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Abstract
Targeted therapy and immunotherapy eradicate malignant cells through different
mechanisms, and the strengths and weaknesses of these two approaches are potentially
complementary. Therefore, the combination of molecular targeted drugs with immunebased therapies is considered an attractive approach for improving the therapeutic
efficacy of cancer treatment. The mutation and amplification of the c-KIT protooncogene are associated with multiple different cancer types, and multiple c-KIT
inhibitors have been tested clinically. In spite of some encouraging results using these
agents, most patients with c-KIT mutant cancers still relapse due to drug resistance. This
also demonstrates the inherent limitation of molecular targeted drugs as mono-therapies,
and highlights the need for combinatorial therapeutic approaches.

In this study, we show in the c-KIT mutant mastocytoma P815 mouse model that the
therapeutic effect of the c-KIT inhibitor dasatinib is substantially dependent on the antitumor T cell response. Even though the direct effect of dasatinib on antigen-driven T cell
expansion is inhibitory, 3-day dasatinib treatment significantly increased the proportion
of tumor-specific T cells in the circulation of the treated mice. We also found that
dasatinib augmented the priming of T cells through inhibition of immunosuppressive
components, including down-regulation of Treg cells and IL-10. When dasatinib was
combined with anti-OX40, an agonistic antibody that provides T cells with a potent
costimulatory signal, we found that the two agents together gave a much better
therapeutic effect compared with either therapy alone, leading to complete tumor
eradication in most of the treated mice. Anti-OX40 alone enhanced the infiltration of
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CD8+ T cells within the tumor microenvironment. Furthermore, the combination of
dasatinib and anti-OX40 significantly up-regulated the expression of IFN-γ-induced Th1
chemokines CXCL 9, 10 and 11, which was consistent with the enrichment of tumorspecific T cells at the tumor sites and better therapeutic effect. This study demonstrates
that combinations of molecular targeted agents with immunotherapeutic approaches may
result in superior therapeutic effects, suggesting that employing a similar combination
strategy may provide clinical benefits to patients with c-KIT mutant cancers.
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Chapter 1. Introduction
1.1 Targeted therapy of cancer
Discoveries of specific proteins and pathways that contribute to the carcinogenesis and
malignant phenotype of cancer cells have led to the generation of therapeutic agents
which can specifically target cancer cells. Unlike chemotherapy and radiation therapy,
which commonly impair rapidly dividing cells, targeted therapy interferes with the
specific pathways necessary for cancer progression and therefore it is considered more
effective and less toxic than conventional treatments. Targeted therapy drugs include
antibodies and small molecule inhibitors. Monoclonal antibodies target specific antigens
either are extracellular growth factors or receptors on cell surface. Binding of the
antibody with the ligand or the receptor could effectively block the activity of that
specific oncogenic pathway. Monoclonal antibodies which have achieved significant
success in the clinic include anti-CD20(Rituximab), anti-VEGF(Bevacizumab), antiEGFR( Cetuximab) and anti-Her2/neu(Trastuzumab). Those monoclonal antibodies have
been used for the treatment of various types of cancers, including breast cancer,
lymphoma, colon cancer and lung cancer(1-5). Small molecule targeted therapy drugs are
another class of agents discovered or structurally designed for oncogenic proteins.
Compared with monoclonal antibodies, this class of drug is less specific because they
normally affect a subset of kinases with similar structure on the targeted domain rather
than block the activity of one target. But the advantage of small molecule inhibitors is
their ability of interfering with intracellular molecules which monoclonal antibodies
cannot(6). Multiple small molecule inhibitors have been approved by FDA for cancer
1

treatment, for example, erlotinib, gefenitib and vemurafenib. And more drugs are being
tested in clinical and preclinical studies(7, 8).

Advent of molecularly targeted agents is considered as a milestone in the history of
cancer therapy. However, the instability and complexity of cancer genome limit the
success of targeted therapy. The responses to targeted therapy are usually of limited
durability. A general phenomenon in patients is the development of drug resistance (911). Multiple mechanisms are involved in the occurrence of drug resistance in patients:
mutation of the target protein could reduce the binding affinity between the drug and the
target; the expression of the target can be up-regulated at DNA, mRNA and protein levels;
enhanced activities of other oncoproteins could compensate for the inhibition of the target
protein; overexpression of the drug transporters could reduce the intracellular drug
concentration; drug-resistant cancer cell clones could outgrow the drug-sensitive
clones(12) . Therefore, it is unlikely that targeted therapy alone can lead to cure.

1.2 C-KIT
C-KIT (CD117) is a tyrosine kinase receptor, which is encoded by the proto-oncogene
KIT located on human chromosome 4 and mouse chromosome 5. Under physiological
condition, this receptor is expressed by hematopoietic  stem  cells,  mast  cells,  melanocytes  
and   interstitial   cells   of   Cajal. Its ligand is stem cell factor (SCF) which is secreted by
endothelial cells and fibroblasts(13). The extracellular part of c-KIT is composed of five
immunoglobulin-like domains, this is the ligand binding domain and is encoded by exon
2-9. The juxtamembrane domain which is believed to have auto-inhibitory function is
2

encoded by exon 11. The intracellular part contains 2 tyrosine kinase domains, one ATPbinding pocket encoded by exon 13 and 14 and one kinase activation loop encoded by
exon17 (Figure 1)(14, 15). Upon the binding of SCF, 2 c-KIT receptors form a dimer and
phosphorylate each other on certain tyrosine residues. The phosphorylated tyrosine
residues serve as the docking sites for multiple effector molecules, then activate a wide
array of downstream signal transduction pathways, including MAPK pathway, PI3K/Akt
and JAK/STAT pathway, which play critical roles in multiple aspects of cellular
functionality(16-18).

The amplification and mutation of this gene are associated with several types of cancer,
including gastrointestinal stromal tumors(GIST), mast cell leukemia, melanoma,
testicular seminoma and acute myeloid leukemia. Mutation of c-KIT could cause the
activation of this receptor without the binding of SCF, and the deregulated activation of
downstream oncogenic pathways leads to the uncontrolled growth and survival of
cells(19, 20). Therefore, c-KIT became an attractive target for the treatment of those
cancers. And multiple c-KIT inhibitors have been developed and applied in clinical
practice.

GIST is derived from c-KIT expressing interstitial   cells   of   Cajal (ICC). Activating
mutation of c-KIT has been found in more than 80% of GIST patients. The most
common genetic aberrations occurring in GIST are duplication of codon 502-503 on exon
9 and V560G mutation on exon 11(13, 21, 22). The tumor is refractory to conventional
chemotherapy and irradiation therapy. However, introduction of c-KIT inhibitors into the
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clinic has significantly improved the prognosis of the patients and change the natural
history of this disease. It is one of the most successful examples showing the
effectiveness of molecular targeted therapy. Currently, imatinib is applied in the clinic for
treating patients with unresectable tumors and patients after surgical removal for
prevention purpose. Another c-KIT inhibitor sunitinib has been shown to be effective in
treating GIST patients who have developed resistance to imatinib(23).

Mutation of c-KIT in the overall melanoma population is at a relatively low frequency,
resulting in the disappointing outcome of early clinical trials using imatinib(24-26). In
2010, Curtin and his colleagues reported that in the rare subsets of acral, mucosal and
chronic sun damaged (CSD) melanoma, incidence rates of c-KIT genetic aberration are
36%, 39% and 28% respectively, which are quite high. The most common mutations are
L576P on exon 11 and K642E on exon 13.While in the subset of melanoma arising from
skin without chronic sun damage, the mutation rate is zero (27). There are multiple
clinical case reports showing that patients with c-KIT mutations respond well to c-KIT
inhibitors such as dasatinib and imatinib(28-31). More clinical trials determining the
therapeutic efficacy of c-KIT inhibitors in melanoma are currently ongoing.

Mastocytosis is not a malignant disease per se, but when it progresses to an advanced
stage, it could evolve into mast cell leukemia. C-KIT mutation drives approximately 95%
of mastocytosis and D816V mutation is identified in 80% of the patient samples(32-34).
In  mastocytosis  cell  lines,  studies  have  demonstrated  that  imatinib  can’t  efficiently inhibit
the activity of c-KIT with D816V mutation, while dasatinib could significantly block its
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activity and lead to the apoptosis of the cells(35). Therefore, dasatinib might be an
effective targeted drug for this disease. C-KIT mutations have also been found in germ
cell tumor and acute myeloid leukemia (core binding factor subtype). The summary of
the various cancers associated with c-KIT mutations as illustrated below(Table 1) (13,
36-38).

5

Figure 1 C-KIT structure and signaling schematic diagram.
The extracellular region is encoded by exons 2 through 9, and contains 5
immunoglobulin-like domains. The Juxtamembrane domain is encoded by exon 11.
There are 2 intracellular tyrosine kinase domains: the ATP-binding pocket encoded by
exons 13 and 14, and the kinase activation loop encoded by exon 17. Binding of SCF
causes the dimerization of c-KIT and autophosphorylation of this receptor, consequently
triggering the activation of downstream Ras/MEK/MAPK, PI3K/Akt and JAK/STAT
pathways.

6
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Table 1 C-KIT genetic aberrations associated with human malignancies
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1.3 Dasatinib
Dasatinib, a small molecule tyrosine kinase inhibitor drug, was originally identified as a
potent Src/Abl inhibitor by researchers at Bristol-Myers Squibb about ten years ago. Due
to its potent anti-proliferative activity against multiple hematological and solid tumor cell
lines, it has been approved by FDA for the treatment of Philadelphia chromosomepositive acute lymphoblastic leukemia and chronic myelogenous leukemia. The targeted
kinase spectrum of dasatinib is quite broad, including Src family members, Bcr/abl, cKIT, PDGFR and Ephrin A. The mechanism dasatinib’s action involves its competitively
binding with the ATP-binding site of the kinase to inhibit the phosphorylation of tyrosine
involved in the signal transduction. The plasma half-life of dasatinib is only 5-6 hours,
quite short compared with other tyrosine kinase inhibitors(39).

This drug is currently being tested in clinical trials for treating multiple solid tumors such
as melanoma, GIST, pancreatic cancer and breast cancer. Even though imatinib is the
most commonly used c-KIT inhibitor in the clinic, dasatinib has been shown to be a
potential stronger inhibitor for certain forms of mutant c-KIT. For example, it has been
shown that L576P, the most common c-KIT mutation in melanoma, is sensitive to
dasatinib rather than imatinib. One study suggests that the different binding affinities of
imatinib and dasatinib might be caused by the different structural changes of the mutant
kinases(31). P815, a tumor cell line with D814Y mutation we used in this model, is also
not sensitive to the inhibition of imatinib, but it is sensitive to killing mediated by
dasatinib. That is why we used dasatinib as the targeted therapy drug in this study(35, 40).

9

1.4 P815 mouse model
P815 is a mastocytoma line induced by a highly carcinogenic compound
methylcholanthrene(MTA) in a DBA/2 mouse. Tumor antigens, from this immunogenic
tumor, have been identified and cloned. P1A, the first tumor antigen identified, is a nonmutated gene normally expressed in the placenta and testis of the DBA/2 mouse. A
transgenic mouse strain with TCR specific for H-2Ld : P1A complex has been generated
and named P1CTL mice. People could utilize these transgenic mice to do adoptive T cell
transfer experiments studying the anti-tumor CTL response in vivo. Another antigen
identified later on is P1E. Therefore, this model allows people to monitor immune
responses against two MHC I-restricted epitopes at the same time. This animal model
has long been considered as a good tool for analyzing the relationship between tumor and
anti-tumor T cell immunity.

Studying the combination of targeted therapy and immunotherapy is quite challenging
due to the low availability of the suitable animal models. We need an immunogenic
tumor, whose growth is driven by a single oncogenic event and can be implanted in
immunocompetent mice. We found that the P815 tumor model fits these criteria. Growth
of P815 is controlled by a mutant c-KIT receptor (D814Y mutation) and disrupting c-KIT
signaling could significantly inhibit the proliferation and promote the apoptosis of this
tumor line. In addition, P815 is a very immunogenic tumor allowing us to study the
therapeutic effect of immunotherapy.

10

1.5 Anti-tumor T cell response
The theory of cancer immune surveillance was developed by Burnet and Thomas in
1950s(41) and it is currently well-accepted that immune system can recognize and
eliminate malignant cells. Both innate components and adaptive components from the
immune system play a role in controlling the growth of cancer cells. NK cells, NKT cells
and macrophages which can directly eliminate the transformed cells are the major players
of innate anti-tumor immune response(42). T cells are the major effectors of the adaptive
anti-tumor immunity. The anti-tumor T cell response is a multi-step process. First, tumor
antigens need to be taken up by dendritic cells, then APCs process the proteins into
peptides and load them to MHC molecules. Activated dendritic cells then migrate into
tumor-draining lymph nodes. When naïve T cells with the specific TCR encounter the
dendritic cells presenting the corresponding peptide, they get activated and undergo
clonal expansion. During this priming phase, number of the T cell precursors specific to
an antigen could increase more than 1000 fold and these cells form a pool of effector
cells. CD8+ effector T cells are normally   considered   as   the   ‘killer   cells’   with   cytolytic  
activity. They migrate into tumor microenvironment following chemokine gradients.
Once encountering tumor cells, CTLs release vesicles containing perforin and granzymes.
Perforin is a cytolytic protein forming pores on the cell membrane of the target cells.
Granzymes are serine proteases which can cleave caspase-3 and activate the downstream
apoptotic pathway in the target cells. Surface expression of FasL is another mechanism
CTLs employ to eliminate tumor cells. Engagement of FasL on CTLs and Fas receptor on
tumor cells activates caspase-8 and triggers the extrinsic apoptotic cascade. Those
molecules are the major mediators of T cell cytolytic activity. CD4+ effector T cells are
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generally considered as the T helper cells which coordinate many elements of the
immune response. They can help activate APCs through CD40-CD40L axis and
production of cytokines, and they also participate in priming CD8+ T cell as well as
activating macrophages(43). Recent studies suggest that a subset of CD4+ T cells might
also possess cytolytic activity and can directly kill tumor cells(44-46). The majority of
the effector T cells die after the effector phase, leaving a small pool of memory T cells
which can elicit more rapid response upon secondary antigen stimulation. Because of the
potent capability of T cells to specifically recognize and eliminate cancer cells, T cellsbased therapies show great promise in developing immune treatment for cancers.

1.6 Immunotherapy of cancer
Cancer immunotherapy is based on the idea of boosting the immune reaction to eradicate
cancer cells. It has been successfully implemented in the clinical treatment of a number
of malignancies, such as lymphoma, renal carcinoma and melanoma(47-53).
Immunotherapy for cancer can be divided into several categories: adoptive cell therapy,
cytokine based therapy, cancer vaccine and antibodies targeting costimulatory molecules,
etc (Table 2).

Adoptive cell therapy (ACT) transfers cytolytic lymphocytes which have been stimulated
or genetically modified ex vivo back into patients. The most effective adoptive cell
therapy approach for cancer so far is adoptive T cell therapy with tumor infiltrating T
lymphocytes (TIL) which involves isolation of TILs from   patients’   resected tumor
masses, ex vivo expansion of isolated TILs to large numbers and re-infusion of those
12

tumor-specific TILs. Clinical responses to ACT in early years were not quite promising,
but adding preparative lymphodepletion regimen significantly improved the response rate
of this therapy(54, 55). The potential mechanisms involve increased availability of
homeostatic cytokines and down-regulation of immune suppressive cells(56). According
to a recent clinical study conducted at the NCI, the overall response rate for patients
receiving chemotherapy-based preparative regimen and ACT was 49%, when adding
12Gy total body irradiation to the standard treatment approach, the overall response rate
was improved to 72%(57). Compared with other therapeutic regimens, ACT turned out to
be the most efficient one for late-stage melanoma patients. Multiple clinical trials are
currently underway to determine the therapeutic efficacy of this immunotherapy approach
in other types of cancers, including renal carcinoma and ovarian cancer (58). One
advantage of this approach is enabling people to directly manipulate the transferred T
cells genetically, which might offer a therapeutic advantage. Genetic modification can be
used to re-direct the antigen specificity, enhance the survival and improve the migration
ability of transferred T cells(59-63).

Cytokine-based therapies have also been successfully implemented in clinical cancer
treatment. The two most successful examples are IFN-α  and  IL-2. IFN-α  is  produced  by  
leukocytes and it is one of the first cytokines that has been found to exhibit anti-tumor
effect. It does not only induce apoptosis in cancer cells but also stimulates the innate and
adaptive immune responses against malignant cells. Therefore, IFN- α  has  been  approved
by the FDA for the treatment of a number of tumors(64). IL-2 is the first interleukin that
has been identified and cloned. It is mainly produced by activated T cells and plays a
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critical role in regulating T cell proliferation, differentiation and survival. In addition to
its function in T cells, IL-2 also exerts pleiotropic effect on other subsets of immune
cells: it could promote the immunoglobulin production by B cells, boost the proliferation
and activation of NK cells and also affect the function of macrophages and dendritic
cells(65). Due to its biological function of expanding and activating cytolytic T cells and
NK cells, IL-2 has been used in the clinic for cancer treatment for a long time. High dose
IL-2 therapy could induce response in 15% of the patients and leads to cure in 5% of the
patients with late-stage melanoma(66). Therefore, it is considered as one of the first-line
treatment options for metastatic melanoma. It is also being used for treating renal
carcinoma and combined with adoptive T cell therapy and cancer vaccines(67). There are
several other cytokines showing promising results in cancer-related studies, such as GMCSF, IL-15 and IL-21. Clinical trials of validating the therapeutic efficacy of those
cytokines are underway.

Vaccines have been successfully used to induce adaptive immune responses against
infections in the clinic. Identification of multiple cancer antigens has paved the way for
the development of cancer vaccine. The concept of cancer vaccine was proposed long
time ago and people have conducted extensive studies to develop all sorts of cancer
vaccine for several decades. Common forms of cancer vaccine include whole cell-based
vaccine, protein-based vaccine, peptide-based vaccine, DNA-based vaccine, recombinant
virus vaccine and dendritic cell vaccine. However, the success of vaccines in cancer
treatment is very limited so far. Taking melanoma as an example, a study published 2
years ago showing that gp100 peptide vaccine combined with IL-2 improved the
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prognosis of late-stage melanoma patients as compared with IL-2 alone is one of the first
clinical studies showing that vaccine could provide certain therapeutic effect in late-stage
cancer patients(68). For most of the cancer vaccine-related clinical trials, the results
turned out to be disappointing. Further studies are needed to improve the therapeutic
efficacy of cancer vaccine.

15

Table 2 Summary of different types of cancer immunotherapy
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1.7 Costimulatory molecules
T cell activation against tumor antigens is a critical step of an effective anti-tumor
immune response. After undergoing the positive selection and negative selection in
thymus, naïve T cells mature and migrate to the peripheral lymph nodes in which they
might encounter the APC presenting the cognate peptide/ MHC complex. This is the socalled ‘first-signal’ for the activation of naïve T cells. And the binding between CD28 on
T cells and CD80/86 on APC is also critical for T cell activation. CD28 activation could
induce the phosphorylation of its tyrosine residues, which recruits proteins with SH-2
domain, such as PI3K and Grb2. Signaling through CD28 enhances the TCR signaling
and activates the expression of certain anti-apoptosis genes, such as bcl-xl. This provides
the  ‘second  signal’  for  T  cell  priming.  However, the fate of T cells is finally determined
by the integration of signals from multiple co-existing molecules in the T cell-APC focal
synapses. In addition to CD28, costimulatory molecules including 4-1BB, OX40, LAG-3,
CD27, BTLA, CTLA-4 , PD-1 and several other ones simultaneously play important
roles in this process. Some of them provide positive signal for T cell activation and some
of them could negatively interfere with T cell function(Figure 2). When naïve T cells
encounter antigen presented in the context of proper costimulation, they could undergo
rapid expansion, differentiation and then become cytotoxic effector cells. However,
negative signals coming from the costimulatory pathways might result in T cell anergy or
exhaustion.
pathways

Progresses in the understanding of the costimulatory molecules-related
has led to the development of several antibodies specific targeting those

molecules. The most successful examples are anti-CTLA-4 and anti-PD-1.
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CTLA-4 is an inhibitory checkpoint molecule expressed by T cells right upon T cell
activation. CTLA-4 competes with CD80/CD86 for receptor binding with CD28. CTLA4 ligation inhibits the activation and expansion of T cells thereby effectively dampens
the magnitude of an immune response including anti-tumor T cell response(69-71).
CTLA-4 blockade could  remove  this  ‘brake’  on  T  cells  activation  and   has been shown to
effectively enhance the anti-tumor immunity in multiple animal models(72, 73).
Ipilimumab, the antagonistic antibody against CTLA-4, demonstrated superior
therapeutic effect when combined with dacarbazine or gp100 vaccine in melanoma
clinical trials(74, 75), thus was approved for the treatment of late-stage melanoma in
2012. Currently, this drug is undergoing clinical trials for treating lung cancer and
prostate cancer patients.

PD-1 is another key negative regulator expressed by T cells. Binding of PD-1 ligands
with PD-1 receptor could render T cells undergo exhaustion and become unresponsive.
This pathway has been well characterized as negatively controlling the T cell response to
chronic viral infection and cancer (76, 77). PD-L1 expression has also been identified in
various types of tumors and currently is considered one of most important immune
evasion mechanisms employed by cancer cells(77-81). Increased knowledge about the
function of PD-1/PD-L1 axis in immune regulation has led to the development of
antagonistic PD-1 and PD-L1 antibodies. The phase I clinical trials have ensured the
safety and tolerability of PD-1 and PD-L1 antibodies, and also showed durable
therapeutic response in some patients. (82-86). Larger clinical trials of treating late-stage
cancer patients with these antibodies are underway.
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The initial success of anti-PD-1 and anti-CTLA-4 has raised hope that costimulatory
antibodies would revolutionize cancer immunotherapy. A number of antibodies against
other costimulatory molecules have been shown to be effective in preclinical studies, for
examples, anti-OX40(87, 88), anti-4-1BB(89, 90) and anti-CD40(91, 92). And studies
trying to develop new humanized antibodies against those T cell regulatory molecules
represent an active area of research.
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Figure 2 Major costimulatory molecules in lymphocytes.
Costimulatory molecules play an important role in regulating the function of lymphocytes.
They can be classified into two types: negative and positive costimulatory molecules.
Important negative costimulatory molecules include programmed cell death protein 1
(PD-1), B and T lymphocyte attenuator (BTLA) , CD160, cytotoxic T lymphocyte
antigen 4 (CTL-4), and lymphocyte activation gene 3 (LAG3). Important positive
costimulatory molecules include CD28, inducible co-stimulator (ICOS), CD137(4-1BB),
OX40, CD27, glucocorticoid-induced TNFR-related protein (GITR), B cell activation
factor receptor (BAFFR), transmembrane activator and CAML interactor (TACI), B cell
maturation antigen (BCMA) and CD40L. Most of those costimulatory molecules belong
to immunoglobulin(Ig) superfamily or tumor necrosis factor receptor (TNFR)
superfamily. The ligands for those molecules are mainly expressed by APCs and other
peripheral cells. Costimulatory pathways are important targets for cancer immunotherapy.

Reprinted by permission from Macmillan Publishers Ltd: Nature Review Drug Discovery
12(2): 130-46, © 2013 Macmillan Publishers Ltd
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1.8 Anti-OX40
OX40(CD134) is a costimulatory molecule which belongs to the tumor necrosis family
receptor (TNFR) superfamily. It is known to play an important role in the proliferation,
differentiation, survival and migration of T cells. OX40 is expressed on T cell after its
activation, with variable dynamics in various conditions. Both TCR signaling and CD28
ligation have regulatory role on the expression of OX40, and certain cytokines, such as
IL-2 and TNF, might also prolong or enhance the expression. But generally, the
expression of OX40 on CD8+ T cells is more transient than CD4+ T cells(93).
OX40L(CD252) is expressed as a trimer on the cell surface of a number subsets of
immune cells, such as dendritic

cells, B cells, and endothelial cells(94). OX40

crosslinking results in OX40 binding with several intracellular adaptors, including
TRAF2, TRAF3 and TRAF5, which leads to the activation of NF-κB   pathway and
PI3K/Akt pathway. This prevents T cell apoptosis by enhancing the expression of bcl-2,
bcl-xl and survivin, and also promotes the division, cytokine production and memory
response formation through some unknown signaling mechanisms(93).

OX40 and OX40L knockout mice were generated more than a decade ago. OX40
deficient mice infected with LCMV and influenza virus demonstrated defective CD4+ T
cell response(95). OX40L deficient mice had reduced dendritic cell mediated-T cell
priming and contact hypersensitivity response(96). These early animal studies suggest
OX40 plays an important role for T cell costimulation. Studies have shown that OX40
activation could help maintain the survival of effector T cells beyond the initial several
rounds of cell division after their encounter with antigen. And OX40 agonist can enhance
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the clonal expansion and formation of memory response for both CD4+ and CD8+ T
cells in vivo(97, 98). In addition, OX40 ligation on Tregs could effectively block the
suppressive function of those cells. Studies have found that OX40 stimulation suppresses
the expression of Foxp3 gene, which is the master regulator of Treg cells, and also
prevents the induction of Treg cells from CD4+ conventional T cells(99-101). Therefore,
the advantage of utilizing OX40 ligation to boost T cell response is affecting both the
effector side and the regulatory side. OX40 has also been shown to be expressed by other
subsets of immune cells, such as NK, NKT and dendritic cells, and affects function of
these cells (102-104).

The OX40-OX40L axis has also been shown to be involved in the pathogenesis of
multiple autoimmune diseases by animal studies. For example, in an induced
experimental autoimmune encephalomyelitis (EAE) model, OX40L knockout mice
exhibited much less severe clinical manifestations than the wild type mice(105). Later on,
animal experiments demonstrated that expression of OX40L on tumor cells could
enhance the tumor immunogenicity and mediate the tumor rejection(106), suggesting
OX40 signaling also plays important role in tumor immunity. Then, agonistic anti-OX40
antibody alone was shown to potentiate the anti-tumor immune response in multiple
tumor models through multiple mechanisms, including promoting effector and memory T
cell response, suppressing Treg function and enhancing the migration of CTL into tumor
microenvironment(88, 107, 108). In addition, the combination of anti-OX40 with
chemotherapy, irradiation therapy and other immunotherapy regimens have also been
tried and showed promising therapeutic effect(109-112). Those studies have paved the
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way for translating OX40 ligation therapy into the clinic. A humanized agonistic antiOX40 antibody has recently been generated and is being tested in clinical trials.

1.9 Mechanisms of cancer immunosuppression
A wide variety of mechanisms are employed by cancer cells to evade or subvert an
immune attack. It is well known that cancer cells can down-regulate their antigen
presentation machinery to avoid being killed by immune effectors. Mutations in genes
encoding MHC molecules, TAP and LMPs are commonly seen in cancer cells(113, 114).
Besides evading the immune attack by impairing the antigen presentation pathway,
cancer cells could also directly exert inhibitory effect on immune effectors by multiple
immunosuppression mechanisms, including producing inhibitory cytokines and enzymes,
recruiting suppressive cells and expressing inhibitory surface molecules(115, 116), which
are listed below(Table 3).

Cancer cells and the stromal cells in the tumor microenvironment could secrete large
amounts of inhibitory cytokines such as IL-10(117), TGF-β  (118) and VEGF(119). These
cytokines can directly inhibit the antigen presentation capability of dendritic cells, the
proliferation and cytolytic function of T cells and cytokine production by immune
effectors. Enzymes with immunosuppression properties also profoundly exist in the
tumor microenvironment. For example, indoleamine 2,3- dioxygenase (IDO)(120),
arginase(121) and inducible nitric oxide synthases (iNOS)(116) could catabolize some
amino acids which are essential for the proliferation and function of T cells. Tumor cells
can produce chemokines, such as CCL22, CCL2 and CXCL2 to attract regulatory T cell
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(Treg), myeloid-derived suppressor cell (MDSC) and M2 tumor-associated macrophage
(TAM) into tumor microenvironment(116, 122, 123). Profound existence of cells with
immune-inhibitory properties substantially hinders the function of anti-tumor immune
cells. Last but not least, cancer cells can express multiple immune-inhibitory molecules,
such as PD-L1 and FasL(124-126). Engagement of those molecules with their
corresponding ligands could lead to T cell exhaustion, anergy or depletion in the tumor
microenvironment. These mechanisms may act in concert to restrain anti-tumor immunity.
Therefore, cancer-induced immune suppression is a major obstacle for the success of
immunotherapy and overcoming it might help eradicate cancer cells successfully.
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Table 3 Immunosuppressive mechanisms employed by cancer

26

1.10 Rationale for combining targeted therapy and immunotherapy
Advances in the development of multiple targeted therapy agents and immunotherapy
approaches in the recent years avail a great opportunity for combinatorial therapies.
There are several rationales for combining these two(127).

Firstly, even though some targeted therapy drugs can induce dramatic tumor shrinkage in
some patients, the responses are usually of limited durability. And although certain
targeted therapy drugs are known to be able to induce a high response rate in the subset
of the patients who have the corresponding mutation, they barely lead to a cure. However,
immunotherapy is quite different. Although the overall response rates for most of the
immunotherapy regimens are relatively low, durable and complete responses do happen
in some patients. In fact, immunotherapy might be the only treatment able to elicit a
memory response against tumor and provide long-term protection against recurrence.
Besides, targeted therapy and immunotherapy eradicate cancer cells by completely
different mechanisms: one is blocking the oncogenic pathway which supports the growth
of tumor cells, another is boosting the cytotoxic immune cells to eliminate tumor cells.
The targeted therapy-resistant cells could still be sensitive to immune-mediated killing,
and tumor cells successfully evade the immune surveillance could still be eliminated by
blocking their growth signaling. Therefore, those two types of treatments have
complementary strengths and weaknesses, and combinatorial therapy might provide
better therapeutic outcomes.
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Secondly, cancer has been proved to utilize multiple mechanisms to suppress the immune
system and evade the immune surveillance. These mechanisms are the major contributors
of cancer immune evasion and cancer-induced immune tolerance. Overcoming hese
barriers is one of the keys to the success of immunotherapy. Recent studies have shown
that certain oncogenic signals could directly up-regulate the immunosuppressive
mechanisms to advance the tumor growth (128, 129). Therefore, the effectiveness of
immunotherapy could be enhanced upon the down-regulation of oncogenic signalmediated immunosuppression. In addition, some non-specific kinase inhibitors have
already been shown to exert suppressive effect on immunosuppressive cells. For example,
sunitinib treatment inhibiting MDSC and Tregs is considered as an additional advantage
of using this drug to treat renal cancer patients(130). Therefore, if targeted therapy can be
employed to down-regulate immunosuppressive components, it could be successfully
integrated into immunotherapy protocol in cancer treatment settings.

Thirdly, the anti-tumor immune response could be induced upon the treatment of a
number of cytotoxic regimens, because the massive death of cancer cells results in release
of tumor antigens. In fact, anti-tumor immune response is one of the parameters
determining the therapeutic outcomes of certain chemotherapies, radiotherapies and
targeted therapies(131). For example, the polymorphism of TLR4 gene could serve as an
independent prognostic factor of the response to anthracycline and local irradiation in
breast cancer patients(132). And a correlation of clinical response with CD8 and IFN-γ  
expression levels was also observed in breast cancer patient receiving chemotherapy(133).
These are all evidences indicating that the anti-tumor immune response might
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substantially contribute to the therapeutic effect of cytotoxic regimens. In addition, it is
well-known that some mutant oncogenic proteins function as tumor antigens eliciting
tumor specific immune response, for example, mutant β-catenin and p53 (134, 135) .
Besides, deep sequencing analysis of cancer genomes also shows that multiple mutations
accumulated in tumor cells could potentially be presented by MHC molecules and
function as target antigens(136). These lines of evidences suggest that tumor debris
generated in situ after targeted therapy treatment could potentially be a great sources of
tumor antigen which might initiate strong anti-tumor immune response with appropriate
boosting strategy.

Therefore, the combinatorial approaches may provide therapeutic synergy and result in
stronger and more durable clinical response. Studies involving combinatorial therapy are
currently ongoing. For example, clinical trial testing the therapeutic efficacy of BRAF
inhibitor vemurafenib and anti-CTLA-4 antibody ipilimumab in melanoma patients is
being conducted at multiple cancer centers.

However, successful implementation of combinatorial regimen in the clinic requires
understanding of the interaction of the targeted agent and immune response. In this study,
we explored the effect of one c-KIT inhibitor dasatinib on anti-tumor T cell response in
this specific model - P815 mastocytoma mouse model. And we operated under the
hypothesis that the therapeutic efficacy of the targeted therapy could be enhanced by
boosting the endogenous anti-tumor immune response with an immune-stimulating
approach. In doing so, we found that the underlying anti-tumor T cell response is an
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important   contributory   factor   of   dasatinib’s   therapeutic   effect   in   this   model   and   the  
combination of dasatinib plus anti-OX40 synergizes to induce a potent anti-tumor T cell
response and provides superior therapeutic effect.
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Chapter 2. Dasatinib elicits a strong tumor-specific T cell response
which contributes substantially to the therapeutic effect of dasatinib
2.1 T cell–mediated immunity contributes to the anti-tumor effects of dasatinib
It has been shown that dasatinib can suppress the c-KIT kinase activity effectively and
inhibit the growth of P815 tumor cells in vitro (35, 40). In our in vitro experiment, we
also showed that dasatinib could induce apoptosis of P815 cells in a dose-dependent
manner by Annexin V+7-AAD staining. Dasatinib could induce the apoptosis of P815
starting at a concentration as low as 10nM (Figure 3A), which indicates that P815 is very
sensitive to dasatinib. To test whether dasatinib could kill P815 in vivo, we inoculate
mice subcutaneously with 2×106 tumor cells on their left abdominal walls and treated the
tumor-bearing mice with daily gavage of vehicle or different doses of dasatinib (5mg/kg,
10mg/kg, 50mg/kg and 150mg/kg) on days 8, 9, and 10 following tumor inoculation. We
found that at the dose of 150mg/kg, dasatinib significantly inhibited the growth of P815
and prolonged mouse survival (Figure 3B and 3C). H&E staining right after dasatinib
treatment revealed extensive vacuolar degeneration in dasatinib-treated tumors,
morphologic changes consistent with significant tumor cell death (Figure 3D). This result
suggested that dasatinib could directly induce the cell death of P815 in vivo.

To assess a potential role for T cell-mediated immunity in the therapeutic efficacy of
dasatinib, we depleted CD4+ and CD8+ T cells in the mice to see how it affected the
therapeutic effect of dasatinib. We gave the tumor-bearing mice monoclonal antibodies
against CD4 or CD8, intraperitoneally, starting from day 8 once a week. Interestingly,
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both CD4+ T cell-depletion and CD8+ T cell-depletion reduced anti-tumor responses in
dasatinib-treated mice almost to the same level as in vehicle-treated mice, effectively
abrogating the survival benefit provided by dasatinib. (Figure 4A and 4B). This result
revealed that an underlying immune response contributes substantially to the therapeutic
anti-tumor effect of dasatinib in this model.
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Figure 3 In vitro and in vivo anti-tumor effect of dasatinib on P815 mastocytoma.
For in vitro experiment, P815 cells were treated with DMSO or dasatinib for 24 hours
then subjected to flow cytometric analysis. For in vivo experiment, DBA/2 mice were
subcutaneously inoculated with P815 tumor cells on day 0. Tumor-bearing mice were
treated with vehicle or dasatinib (150 mg/kg) on day 8, 9 and 10 by gavage. (A) Dot plots
for Annexin V + 7-AAD staining of treated P815 tumor cells. (B) Tumor sizes in mice
treated with vehicle or dasatinib (*P < 0.05). (C) Kaplan-Meier survival curves of the
tumor-bearing mice for 2 different groups (*P < 0.05). (D) Representative H&E -stained
slides of control tumor and dasatinib-treated tumor.

This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G,
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by antiOX40. Blood. 2012; 120(23): 4533-43. © the American Society of Hematology
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Figure 4 The in vivo anti-tumor effect of dasatinib is dependent on T cells.
Mice  were  injected  i.p.  with  200μg  Rat  IgG  or  CD4  or  CD8  depletion  antibodies starting
from day 8 once a week. (A) Tumor sizes of CD4+/CD8+ T cell depletion experiment
(Vehicle+IgG versus Dasatinib +IgG: *P < 0.05). (B) Kaplan-Meier survival curves of
CD4+/CD8+ T cell depletion experiment (Vehicle+IgG versus Dasatinib +IgG: *P =
0.05).

This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G,
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by antiOX40. Blood. 2012; 120(23): 4533-43. © the American Society of Hematology
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2.2 Short-term dasatinib treatment can increase levels of circulating tumor antigenspecific T cells rather than long-term dasatinib treatment

We next sought to determine the effect of dasatinib on the tumor antigen-specific T cell
response. P815 is an immunogenic tumor which can elicit spontaneous T cell priming
against tumor antigens. To see how dasatinib affected the anti-tumor T cell immunity, we
collected the blood of the mice on day 18. Using a P1A-specific tetramer and flow
cytometry, we found that 3 days of dasatinib treatment significantly increased the tumor
antigen-specific T cell levels in the peripheral blood of tumor-bearing mice (Figure 5A
and 4B). Peripheral blood T cells were also examined for antigen-specific IFN-γ  
production using intracellular staining following stimulation with or without P1A, P1E
peptides for 6 hours. We found that while CD8+ T cells from vehicle-treated mice were
relatively unresponsive to peptide stimulation, a significant proportion of CD8+ T cells
from dasatinib-treated mice showed IFN-γ  positivity  (Figure 5C and 5D). IFN-γ  ELISA  
showed results consistent with the intracellular IFN-γ   staining,   which   indicated   that   3  
days of dasatinib treatment significantly augmented the anti-tumor T cell response
(Figure. 5E). Moreover, CD4+ T cell depletion in vivo significantly compromised the
enhanced tumor antigen-specific CD8+ T cell response mediated by dasatinib (Figure 5F),
suggesting that the CD8+ T cell response against P815 is T helper cell-dependent. This
result also partially explains why in the T cell-depletion experiment, CD4+ T celldepletion abrogated the therapeutic benefit provided by dasatinib as well as CD8+ T celldepletion did.
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However, dasatinib is a multiple tyrosine kinase inhibitor which inhibits the activities of
c-KIT, EphA, Src family members, Brc/abl , PDGFR and some other tyrosine kinases
(39). It has been reported that dasatinib inhibits TCR signal transduction, cellular
proliferation and cytokine production by T cells upon antigen stimulation probably due to
the inhibitory effect of dasatinib on Src family member Lck (137, 138). So to test
whether dasatinib has the same effect on the P1A-specific T cells, we first isolated the
splenocytes from P1CTL transgenic mice, whose TCRs are specific for P1A
peptide/H2Ld complexes. Then we cultured the CFSE-labeled splenocytes in the presence
of P1A peptide and different concentrations of dasatinib for 48 hours. Flowcytometry
showed that dasatinib inhibited the antigen-driven T cell expansion at a dose dependent
manner (Figure 6A). We also cocultured pre-activated P1CTL T cells with P815 tumor
cells or P1A peptide in the presence of different concentrations of dasatinib for 24 hours,
and the harvested supernatants were subject to IFN-γ  ELISA. ELISA result showed that
dasatinib significantly inhibited the cytolytic activity of P1A-specific T cells against
P815, starting at a concentration as low as 10nm(Figure 6B). These results are consistent
with the previous study showing that dasatinib, like other multiple tyrosine kinase
inhibitors, directly inhibits T cell proliferation and activity.

Since we observed enhanced T cell response using a 3-day dasatinib regimen, which was
in contrast with the direct effect of dasatinib on T cell response in vitro, next we
investigated whether increasing the length of dasatinib treatment is harmful or helpful to
its therapeutic effect on P815. We found that prolonged dasatinib treatment   didn’t  
provide any enhanced anti-tumor effects or survival benefit compared with short-term
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dasatinib treatment (Figure 7A and 7B). In fact, P1A tetramer staining showed that longterm dasatinib treatment actually compromised the positive effect of dasatinib on tumor
antigen-specific CD8+ T cell priming (Figure 7C), the P1A tetramer+ T cell level in 8day treatment group was significantly lower than that in 3-day treatment group. Our data
together with results from other groups suggest that antigen-specific T cell responses can
be impaired with the persistent presence of dasatinib, but this drug is still capable of
enhancing anti-tumor immune responses if the dosing and schedule are optimized.
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Figure 5 Effect of dasatinib treatment on tumor antigen-specific T cell response.
Peripheral blood of the treated mice was collected and subjected to flow cytometric
analysis on day 18. Cells were also stimulated with P1A and P1E peptides for IFN- γ  
ELISA. (A) Representative dot plots for P1A tetramer staining in the peripheral blood of
vehicle or dasatinib-treated mice. (B) Percentage of P1A tetramer+ T cells in total CD8+
T cells (*P < 0.05). (C) Representative dot plots for intracellular IFN-γ   staining.   (D)  
Percentage of IFN-γ+  T  cells  in  total  CD8+  T  cells  (P1A:  *P  <  0.05,  P1E:  *P  <  0.05).  (E)  
IFN-γ  secretion by peripheral blood T cells in response to the stimulation of P1A or P1E
peptides detected by ELISA. (P1A: *P < 0.05, P1E: **P < 0.01). (F) P1A tetramer
staining of CD4+ T cell depletion experiment.

This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G,
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by antiOX40. Blood. 2012; 120(23): 4533-43. © the American Society of Hematology
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Figure 6 Effect of dasatinib on T cell proliferation and cytolytic activity in vitro.
For proliferation assay, splenocytes from P1CTL transgenic mice were labeled with
CFSE and cultured with P1A peptide and 0nm, 1nm, 5nm, 10nm, 25nm or 50nm
dasatinib. For IFN-γ   release   assay,   P1A-specific T cells were cultured alone or with
P815 cells or with P1A peptide for 24 hours. (A) Histograms of the CFSE (FITC channel)
gated on CD8+ cells 48 hours after labeling. (B) IFN-γ  secretion  by  P1A-specific T cells
detected by ELISA.

42

43

Figure 7 Therapeutic effects of short-term dasatinib treatment versus long-term
dasatinib treatment.
(A) Tumor sizes in mice treated with vehicle or 3-day dasatinib or 8-day dasatinib. (B)
Kaplan-Meier survival curves of mice treated with vehicle or 3-day dasatinib or 8-day
dasatinib. (C) Percentage of P1A tetramer+ T cells in total CD8+ T cells for these 3
groups (Vehicle versus 3-day dasatinib: **P < 0.01, 3-day dasatinib versus 8-day
dasatinib: *P < 0.05).

This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G,
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by antiOX40. Blood. 2012; 120(23): 4533-43. © the American Society of Hematology
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2.3 Dasatinib down-regulates certain immunosuppressive components in P815 tumorbearing  mice,  which  mediates  dasatinib’s  effect  of  enhancing  anti-tumor T cell
response.

2.3.1 APCs from dasatinib-treated  mice  don’t present more tumor antigen than the
APCs from control group.
One of the most possible mechanisms to explain why there are higher levels of P1Aspecific T cells in dasatinib treated-mice is: drug-induced apoptosis of tumor cells could
generate tumor debris which might be taken up by APCs, and the tumor antigens
presented by the APCs might mediate the priming of tumor-specific T cells. To test
whether this hypothesis is valid here, we set out to assess the amount of tumor antigen
P1A presented by the APCs in the tumor-draining lymph nodes with or without dasatinib
treatment. After we treated the mice with vehicle or dasatinib, we isolated the tumordraining lymph nodes and sort out CD11b+ CD11c+ dendritic cells and coculture them
with pre-activated P1A-specific T cells overnight in the presence of Golgi-Plug, after
which IFN-γ   intracellular   staining   was   done   to   assess   the   reactivation   of   those   T   cells.  
We found that levels of antigen presented by the dendritic cells between these two groups
were not significantly different. The IFN-γ   production   of   the   P1A-specific T cells after
stimulation was comparable in these two groups, which indicated that there was not more
tumor antigen presented by APCs to T cells after dasatinib treatment (Figure 8).
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Figure 8 IFN-γ  staining  of  P1A-specific T cells stimulated with dendritic cells from
lymph nodes of the vehicle or dasatinib-treated mice.
Splenocytes from P1CTL transgenic mice were collected and culture with IL-2 and antiCD3 for 7 days. CD11b+CD11c+ cells from the lymph nodes of the treated mice were
sorted out by FACS. P1A-specific T cells and dendritic cells were co-cultured for 8 hours
and then subjected to flow cytometric analysis. Dot plots show the IFN-γ   intracellular  
staining of P1A-specific T cells.
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2.3.2 Dasatinib treatment can decrease the proportion of regulatory T cells and
enhance vaccine-mediated T cell priming, but doesn’t  decrease  the  proportion  of  
myeloid-derived suppressor cells (MDSC)

Dasatinib has been reported to suppress the proliferation and function of Treg cells in
vitro(139), but the in vivo effect of dasatinib treatment on murine Treg cells has not been
reported. Flow cytometric analysis showed that dasatinib alone significantly decreased
the percentage of Foxp3+CD25+ Treg cells in total CD4+ T cells in the peripheral blood
of tumor-bearing mice (Figure 9A and 9B). The ratio of Tregs to CD8+ effector T cells
was also markedly decreased by dasatinib (Figure 9C). We also examined the Treg levels
within the tumor microenvironment immediately following treatment and found a similar
decrease in dasatinib group (Figure 9D). However, this decrease was transient, as Treg
cell numbers went back to normal 3 days after drug withdrawal (9E).

Because fast-growing tumors are usually accompanied by expansion of Treg cells, to
identify whether this dasatinib-induced decrease in the Treg proportion was due to
decreased tumor volume or a direct inhibitory effect of dasatinib on Treg, we treated
tumor-free mice with dasatinib for 3 days. We observed a similar decrease in Treg cells
in the dasatinib-treated tumor-free mice, suggesting that dasatinib has a direct inhibitory
effect on Treg cell levels (Figure 10A). Since the drop in Tregs was significant, we next
investigated whether the short Treg-depleted window caused by dasatinib can render T
cells more amenable to vaccine-induced antigen-specific expansion in a tumor-free
system. We i.v. injected the mice with splenocytes from P1CTL transgenic mice. After 3
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days of dasatinib treatment, P1A peptide-pulsed dendritic cells were transferred into the
recipients. Flow cytometric analysis of peripheral blood on day 7 after vaccination
showed that magnitude of P1A-specific T cell expansion was significantly higher in
dasatinib-treated group(Figure 10B and 10C). Therefore, this result supports the idea that
dasatinib preferentially decreases Tregs in vivo and makes the host immune environment
more favorable for antigen-driven effector T cell proliferation.

We also checked myeloid-derived suppressor cell levels in those mice. Peripheral blood
samples of the tumor-bearing mice after 3-day dasatinib treatment were collected and
subjected to flow cytometric analysis. In mice, cells expressing Gr1 and CD11b are
considered as MDSCs(140). To further distinguish between subset of MDSCs, we also
stained for another marker Ly6C. Ly6Chigh population is monocytic MDSC and Ly6Clow
population is granulocytic MDSC(141, 142). We found that dasatinib   treatment   didn’t  
significantly change the proportion of MDSCs in leukocyte population. And the
percentages of granulocytic and monocytic MDSCs were not affected by drug treatment
either. We also did complete blood count test (CBC) for peripheral blood samples, and
data showed that 3-day dasatinib   treatment   didn’t   significantly   change the leukocyte
counts in treated mice(Figure 11). It has been shown that other c-KIT inhibitors such as
imatinib and sunitinib can down-regulate MDSC level in animal models and cancer
patients(130, 143).  However,  in  our  study,  we  didn’t  observe  significant  drop  of  MSDCs
after dasatinib treatment. Therefore, it is unlikely that the augmented T cell response in
dasatinib-treated mice is attributed to the change in the MDSC population.
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Figure 9 Effect of 3-day dasatinib treatment on levels of regulatory T cells.
Peripheral blood of the treated mice was collected and subjected to flow cytometric
analysis on day11 and day14. (A) Representative dot plots for Treg staining in the
peripheral blood of tumor-bearing mice on day11. (B) Percentage of Treg cells in CD4+
T cells in the peripheral blood of tumor-bearing mice on day11(***P < 0.001). (C)
Treg/CD8+ T cell ratio in the peripheral blood of tumor-bearing mice on day11(***P <
0.001). (D) Percentage of Treg cells in CD4+ T cells in tumors on day11 (*P < 0.05). (E)
Percentage of Treg cells in CD4+ T cells in the peripheral blood of tumor-bearing mice
on day14.

This research was originally published in Blood. Yang Y, Liu C, Peng W, Lizée G,
Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to
the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by antiOX40. Blood. 2012; 120(23): 4533-43. © the American Society of Hematology
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Figure 10 Effect of 3-day dasatinib pre-treatment on vaccine-mediated T cell
priming.
(A) Percentage of Treg cells in CD4+ T cells in the peripheral blood of tumor-free mice
(**P < 0.01) after 3-day vehicle or dasatinib treatment (B) Treg/CD8+ T cell ratio in the
peripheral blood of tumor-free mice after 3-day vehicle or dasatinib treatment (*P < 0.05)
(C) Representative dot plots for P1A tetramer staining in the peripheral blood on day 7
after vaccination. (D) Percentage of P1A tetramer+ T cells in total CD8+ T cells on day 7
after vaccination( ***P < 0.001).
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Figure 11 Effect of 3-day dasatinib treatment on levels of MDSC.
Peripheral blood of the treated mice was collected and subjected to flow cytometric
analysis and CBC test on day 11. (A) Representative dot plots for MDSC staining in the
peripheral blood of tumor-bearing mice. (B) Percentage of MDSC in leukocytes in the
peripheral blood of tumor-bearing mice. (C) Percentage of monocytic MDSC in
leukocytes in the peripheral blood of tumor-bearing mice. (D) Percentage of granulocytic
MDSC in leukocytes in the peripheral blood of tumor-bearing mice. (E) Leukocyte count
in the peripheral blood of tumor-bearing mice.
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2.3.3 Down-regulation of IL-10 production by tumor cells is another factor
contributing  to  dasatinib’s  effect  of  enhancing  anti-tumor T cell response.
Profound immunosuppression is commonly found within the tumor microenvironments
of various types of cancer. And it is one of the most critical mechanisms of tumor
immune evasion. Therefore, it is possible that there are some immune modulatory
components existing in the tumor microenvironment have contributed to the enhanced
anti-tumor T cell response after dasatinib treatment. To investigate whether any changes
in immunomodulatory gene expression occurred in the tumor microenvironment after 3
day dasatinib treatment, tumor samples were harvested and analyzed for changes in
transcription profiles using gene expression microarray. In P815 tumor microenvironment
with or without dasatinib treatment, expression levels of certain immunomodulatory
genes were quite different. One of the most significant changes observed among the
immune-related genes was that of IL-10 transcription. Dasatinib treatment significantly
down-regulated the level of IL-10 mRNA in the tumor microenvironment (Figure 12).
Considering that IL-10 is a well-known immunosuppressive cytokine, this might suggest
that IL-10 down-regulation is one of the mechanisms contributing to the enhanced antitumor immune response in dasatinib-treated mice. Next, we wanted to determine the
protein levels of immunomodulators in tumor microenvironment by Luminex analysis.
The results also showed a significant decrease in IL-10 production after dasatinib
treatment (Figure 13).

To determine whether the down regulation of IL-10 in the tumor microenvironment was
relevant for the improved anti-tumor T cell response induced by dasatinib, we gave mice
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anti-IL-10 blocking antibody after starting dasatinib treatment and monitored the tumor
growth and anti-tumor T cell response. We found that IL-10 blockade significantly
suppressed the tumor growth and improved the survival of the mice (Figure   14A   and  
14B). Tetramer staining showed that compared with control group, blocking IL-10 also
helped T cell priming (Figure 14C). This result suggested that the down-regulation of this
tumor-derived immunosuppressive cytokine after targeted therapy treatment is another
factor contributing to the anti-tumor T cell response induced by dasatinib.

The notion that constitutive activation of oncogenic pathways could up-regulate a number
of immunosuppressive mechanisms has been supported by several recent studies (129,
144). For example, one study has shown that c-KIT signaling regulates the expression
levels of IDO, an enzyme which can convert tryptophan into immunosuppressive
metabolites in GIST. Furthermore, imatinib treatment suppresses the activation of the cKIT pathway, thereby inhibiting the production of IDO by tumor cells and reactivating
the T cell-mediated anti-tumor immune response (128). This study revealed a link
between c-KIT and an immunosuppressive molecule. Therefore, it is possible that a link
between c-KIT signaling and other immunoregulatory cytokines, such as IL-10, also
exists. Besides, ERK and p38 activation have been shown to be involved in IL-10
expression (145, 146), and both are downstream molecules in the c-KIT activation
pathway. Therefore, we next set out to determine the effect of c-KIT signaling on the
transcription of immune-related molecules, especially IL-10.  We  knocked  down  c-KIT  by  
siRNA  (Figure  15A  and  15B)  and  used  microarray  analysis  to  assess  how  the  expression  
of  immunomodulatory  gene  products  was  affected.  We  also  treated  P815  tumor  cells  with  
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DMSO   or   25nm   dasatinib   in   vitro   for   24   hours   and   analyzed   those   samples   by  
microarray.  We  found  that  certain  immune-related  gene  expression  levels  were  altered  by  
c-KIT   knockdown:   for   example,   IL-4,   IL-6   and   IL-13;;   however,   these   changes   were  
moderate  and  not  significant.  In  contrast  to  what  we  found  in  the  microarray  analysis  of  
in   vivo   dasatinib   treatment,   IL-10   mRNA   levels   in   c-KIT   knockdown   P815   tumor   cells  
and  in  vitro  dasatinib-treated  P815  tumor  cells  were  higher  than  the  control  cells  (Figure  
16),   indicating   that   the   decreased   level   of   IL-10   in   the   tumor   microenvironment   after  
targeted   drug   treatment   is   not   dictated   by   the   ‘   tune-down’   of   the   oncogenic   c-KIT  
signaling  in  this  tumor  model,  but  may  have  been  caused  by  the  decreased viability of IL10-producing tumor cells directly. Still, our study suggests that the decreased  production  
of   immunosuppressive   cytokines   caused   by   targeted   agent-mediated   tumor   cell   death  
might augment T cell priming, contributing to the anti-tumor immune response and
preventing the tumor immune escape.
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Figure 12 Gene expression profiles of P815 tumors treated with vehicle or dasatinib.
24 hours after vehicle or dasatinib treatment, P815 tumors were harvested and subjected
to microarray analysis. 20 most differentially expressed immune-related genes were
selected based on the fold changes of the means of the 2 samples in each group. Heatmap
shows the color-coded expression levels of the selected immune-related genes for tumor
samples treated with vehicle or dasatinib.
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Figure 13 Cytokine profiles in the tumor microenvironment of P815 tumors treated
with vehicle or dasatinib.
After 3-day vehicle or dasatinib treatment, tumors were harvested and subjected to
Luminex assay. Bar graphs show cytokine profiles in the lysates of vehicle or dasatinibtreated P815 tumors (For IL-10, Vehicle versus Dasatinib: *P< 0.05).
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Figure 14 Effect of IL-10 blockade on tumor growth, survival and T cell response.
Mice   were   injected   i.p.   with   200μg   control   IgG   antibody   or   IL-10 blocking antibody
starting from day 8 once a week and also treated with vehicle or dasatinib on day 8, 9 and
10. Peripheral blood of the treated mice was collected and subjected to flow cytometric
analysis on day 18. (A)Tumor sizes for 3 different groups (Vehicle+IgG versus
Vehicle+anti-IL-10 : *P < 0.05). (B) Kaplan-Meier survival curves for 3 different groups
(Vehicle+IgG versus Vehicle+anti-IL-10: *P < 0.05). (C) Percentage of P1A tetramer+ T
cells in total CD8+ T cells (Vehicle+IgG versus Vehicle+anti-IL-10 : *P < 0.05).
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Figure 15 SiRNA-mediated c-KIT knockdown in P815 cells
P815 cells were transfected with non-targeting siRNA or siRNA against c-KIT. 24 hours
after transfection, P815 cells were harvested and subjected to realtime PCR and flow
cytometric analysis. (A)Taqman realtime PCR shows c-KIT mRNA levels in P815 cells
transfected with non-targeting siRNA (NT RNA) or siRNA against c-KIT or no
siRNA.(*P < 0.5). (B) Histogram shows the c-KIT protein levels in P815 cells
transfected with non-targeting siRNA (NT RNA) or siRNA against c-KIT or no siRNA.
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Figure 16 Gene expression profiles of P815 tumor cells.
P815 cells were transfected wit c-KIT siRNA pool or non-targeting pool. 24 hours or 36
hours after transfection, P815 cells were harvested and subjected to microarray analysis.
P815 cells were also treated with DMSO or dasatinib in culture for 24 hours and then
subjected to microarray analysis. Heatmap shows the color-coded expression levels of the
selected immune-related genes for P815 cells.
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Chapter 3. The therapeutic effect of dasatinib on P815 and underlying
anti-tumor responses are potentiated by anti-OX40
3.1 Addition of anti-OX40 antibody improves the anti-tumor efficacy of dasatinib
treatment.
Since we found that the anti-tumor effects of dasatinib were largely dependent on CD8+
T cells, we hypothesized that providing further co-stimulation of these T cells with
agonistic antibodies could further boost the therapeutic response. Since anti-CTLA-4 and
anti-PD-1 are costimulatory antibodies already available in the clinic, we decided to try
these 2 antibodies. Anti-OX40 is a highly promising agonistic antibody currently
undergoing preclinical and clinical investigation, so we also include this antibody in our
initial screening. We treated 8-day tumor-bearing mice with dasatinib or vehicle for 3
days and then administered 2 doses of these 3 antibodies on days 10 and 13 (Figure 17).
As indicated by the survival curve of the tumor-bearing mice, combination of dasatinib
and anti-OX40 gave the best anti-tumor effect. Survival curve indicated that neither the
combination of dasatinib with anti-CTLA-4 nor combination of dasatinib with anti-PD-1
provided synergistic therapeutic effect. While combining dasatinib with anti-OX40 led to
significantly enhanced tumor regression and complete cure in 75% of the mice (Figure
18A-C). The therapeutic effect of the combination treatment was striking considering the
large tumor burden (60mm2-80mm2) at the time of treatment. To determine whether T
cells are the major mediator of this therapeutic effect, mice were injected with CD4 or
CD8 depletion antibodies starting from day 8 once a week. Depletion of CD8+ , and to a
lesser extent CD4+, T cells abolished the therapeutic effect of dasatinib combined with
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anti-OX40 (Figure 18D), supporting the notion that T cells are the major immune effector
cells responsible for the therapeutic effect of this combination regimen.
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Figure 17 Therapeutic effect of combining dasatinib with anti-OX40/anti-PD-1/antiCTLA-4 antibody.
Mice received daily gavage of vehicle or dasatinib (150mg/kg) on day 8-10 and i.p.
injection of IgG control antibody or 200µg anti-OX40 or 200µg anti-PD-1 or 100ug antiCTLA-4 on day 10 and 13. (A) Schema of treatment. (B) Kaplan-Meier survival curves
of the tumor-bearing mice for 8 different groups.
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Figure 18 Therapeutic effect of combining dasatinib and anti-OX40.
(A)Tumor sizes for 4 different groups (Vehicle+IgG versus Dasatinib+anti-OX40: ***P
< 0.001, Dasatinib+IgG versus Dasatinib+anti-OX40: **P < 0.01, Vehicle+anti-OX40
versus Dasatinib+anti-OX40: *P < 0.05). (B) Kaplan-Meier survival curves of the tumorbearing mice for 3 different groups (Vehicle+IgG versus Dasatinib+anti-OX40: ***P <
0.001, Dasatinib+IgG versus Dasatinib+anti-OX40: **P < 0.01, Vehicle+anti-OX40
versus Dasatinib+anti-OX40: *P < 0.05). (C) Plots represent the tumor size of individual
mice for each group. (D) Kaplan-Meier survival curves of CD4+/CD8+ T cell depletion
experiment.
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3.2 The combination regimen increases the infiltration of tumor-specific CD8+ T cells
in the tumor microenvironment.

Although it has been reported that OX40 agonist therapy can enhance the expansion and
survival of CTL(111), we found that addition of anti-OX40 to the dasatinib regimen did
not further enhance or prolong the tumor antigen-specific T cell response in our tumor
model: the percentages of P1A tetramer+ CD8+ T cells were similar between the
dasatinib-treated group and the combination-treated group (Figure 19A-D). Considering
that the combination treatment yielded a much better therapeutic effect than dasatinib
alone, we next sought to assess the effect of this combination regimen on T cell
infiltration of the tumor site. Thus, tumor infiltrating lymphocytes were isolated from
P815 tumors on day 16 and subjected to flow cytometric analysis. We found that antiOX40 alone increased the overall infiltration of CD8+ effector T cells, as previously
reported. And the combination of dasatinib and anti-OX40 led to enhanced infiltration of
P1A-specific T cells into the tumors, to levels greater than that observed with either antiOX40 or dasatinib alone (Figure. 20A and 20B). IFN- γ  staining  of  TILs  also  showed  that  
mice receiving the combination demonstrated the highest levels of IFN-γ production in
response to P1A antigen stimulation (Figure 20C). This result is consistent with a model
whereby dasatinib enhances the level of circulating tumor-specific T cells and anti-OX40
helps those CTL migrate into tumor site.
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Figure 19 Effect of dasatinib and anti-OX40 treatment on the level of the P1Aspecific T cells in the peripheral blood.
Peripheral blood of the treated mice was collected and subjected to flow cytometric
analysis on (A) day 14, (B) day 18, (C) day 21 and (D) day 26. Graphs show the
percentages of P1A tetramer+ cells in CD8+ T cells.
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Figure 20 Influence of dasatinib and anti-OX40 treatment on the tumor infiltrating
lymphocytes.
(A) Total number of CD8+ T cells and the ratio of CD8+ T cells number/tumor weight
(For CD8+ T cells total number, Vehicle+IgG versus Vehicle+anti-OX40: ***P < 0.001,
Dasatinib+IgG

versus

Dasatinib+anti-OX40:

*P

<

0.05,

Vehicle+IgG

versus

Dasatinib+anti-OX40: *P < 0.05; For CD8+ T cells number/gram, Vehicle+IgG versus
Vehicle+anti-OX40: ***P < 0.001, Dasatinib+IgG versus Dasatinib+anti-OX40: *P <
0.05, Vehicle+IgG versus Dasatinib+anti-OX40: **P < 0.01). (B) Total number of P1A
tetramer+ CD8+T cells and the ratio of P1A tetramer+ CD8+ T cells number/ tumor
weight (For P1A tetramer+ T cells total number, Vehicle+anti-OX40 versus
Dasatinib+anti-OX40: *P < 0.05, Dasatinib+IgG versus Dasatinib+anti-OX40: **P <
0.01, Vehicle+IgG versus Dasatinib+anti-OX40: **P < 0.01; For P1A tetramer+ T cells
number/gram,

Vehicle+anti-OX40

Dasatinib+IgG

versus

versus

Dasatinib+anti-OX40:

Dasatinib+anti-OX40:
*P

=

0.05,

*P

<

Vehicle+IgG

0.05,
versus

Dasatinib+anti-OX40: *P < 0.05). (C) Total number of IFN-γ+  CD8+T  cells  and  the  ratio  
of IFN-γ+   CD8+T   cells   number/tumor   weight   (For   IFN-γ+   T   cells   total number,
Vehicle+anti-OX40 versus Dasatinib+anti-OX40: ***P < 0.001, Dasatinib+IgG versus
Dasatinib+anti-OX40: ***P < 0.001, Vehicle+IgG versus Dasatinib+anti-OX40: ***P <
0.001; For IFN-γ+   T   cells   number/gram,   Vehicle+anti-OX40 versus Dasatinib+antiOX40: *P < 0.05, Dasatinib+IgG versus Dasatinib+anti-OX40: *P = 0.05, Vehicle+IgG
versus Dasatinib+anti-OX40: *P <0.05 )
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3.3 The combination of dasatinib and anti-OX40 leads to up-regulation of IFN-γ  and  
IFN-γ induced chemokines in the tumor microenvironment.

Since the repertoire of chemokines at the tumor site is an important determinant for
whether sufficient CTL can be recruited to mediate a successful immune response, we
next sought to determine whether the combination regimen impacted the chemokine
profile within the tumor microenvironment. Quantitative RT-PCR was used to assess the
transcript expression of a panel of chemokines. The results showed that the combination
of dasatinib and anti-OX40 significantly increased the expression of the IFN-γ   induced  
chemokines CXCL9, 10 and 11 in the tumor microenvironment compared with other
groups (Figure 21). The high levels of CXCL 9, 10 and 11 in the combination treatment
group correlated with an increased proportion of tumor-infiltrating antigen-specific T
cells, and improved therapeutic efficacy. This result suggests that induction of IFN-γ  
associated chemokines may induce the migration of effector T cells into tumors to induce
strong anti-tumor immunity following dasatinib plus anti-OX40 treatment.
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Figure 21 Levels of CXCL9, 10 and 11 in tumors from 4 different groups.
Tumors were harvested on day 16 after tumor inoculation. Real-time PCR was performed
to detect the chemokine levels in the tumor microenvironment. GAPDH was used as the
normalization reference gene. Graph shows the normalized fold expression of CXCL 9,
10 and 11 (CXCL9: ***P <0.001, CXCL10: *P < 0.05, CXCL11: *P < 0.05).
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3.4 Combining dasatinib with anti-OX40  leads  to  a  ‘dual  inhibition’  of  Treg  and
increases the CD8+ T cell / Treg ratio in the tumor microenvironment.

Next, we investigated the effect of this combination on Treg levels and function. Flow
cytometric analysis of peripheral blood on day 11 showed that the addition of anti-OX40
to  dasatinib  didn’t  further down-regulate Treg levels, but Treg levels in the combination
group remained much lower than that in the control group(Figure 22A and 22B). Since
both dasatinib and anti-OX40 have been shown to exert inhibitory effects on Treg
function(100, 101, 139), we performed a Treg suppression assay to characterize Treg
function in these mice. CD4+CD25high cells were isolated from the spleens of drugtreated mice and cultured with CFSE-labeled T effector cells, and the proliferation of the
T effector cells was analyzed by flow cytometry 3 days later. We found that the
combination of dasatinib and anti-OX40 resulted in Tregs with less suppressive function
compared with the other three groups, suggesting that inhibition of Treg function
provides an additional benefit of combining these two agents together(Figure 22C). We
also examined the effect of this combination on Treg levels in the tumor
microenvironment on day 16. The numbers of the Treg cells infiltrating tumors were
highly variable, with no statistically significant differences between the groups(Figure
22D). However, we did find that the combination regimen significantly increased the
ratio of CD8+ effector T cells to Treg cells within the tumor microenvironment (Figure
22E), which is known to be favorable for T cell-mediated tumor rejection.
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Figure 22 Effect of dasatinib and anti-OX40 treatment on the level and function of
regulatory T cells.
(A) Percentage of Treg cells in CD4+ T cells in the peripheral blood on day 11
(Vehicle+IgG versus Dasatinib +IgG: ***P <0.001, Vehicle+anti-OX40 versus
Dasatinib+anti-OX40: **P < 0.01, Vehicle+IgG versus Dasatinib+anti-OX40: *P <0.05).
(B) Treg/CD8+ T cell ratio in the peripheral blood on day11 (Vehicle+IgG versus
Dasatinib +IgG: ***P <0.001, Vehicle+anti-OX40 versus Dasatinib+anti-OX40: **P <
0.01, Vehicle+IgG versus Dasatinib+anti-OX40: *P <0.05) (C) Influence of dasatinib and
anti-OX40 on the function of Tregs isolated from 4 different groups (Vehicle+IgG versus
Dasatinib+IgG: *P < 0.05 Vehicle+IgG versus Vehicle+anti-OX40: *P < 0.05,
Dasatinib+IgG versus Dasatinib+anti-OX40: **P < 0.01, Vehicle+anti-OX40 versus
Dasatinib+anti-OX40: *P < 0.05, Vehicle+IgG versus Dasatinib+anti-OX40: ***P <
0.001 ). (D) Total number of Tregs in tumor infiltrating lymphocytes on day 16. (E) Ratio
of CD8+ T cell/Treg in tumor infiltrating lymphocytes on day 16 (Vehicle+anti-OX40
versus Dasatinib+anti-OX40: **P < 0.01, Dasatinib+IgG versus Dasatinib+anti-OX40:
*P <0.05, Vehicle+IgG versus Dasatinib+anti-OX40: ***P < 0.001).
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3.5 The therapeutic effect of 3-day dasatinib combined with anti-OX40 is better than 8day dasatinib combined with anti-OX40
Although 3-day dasatinib and 8-day dasatinib achieved similar overall therapeutic effect
in P815 tumor-bearing mice, we showed these 2 regimens were quite different in terms of
inducing anti-tumor immunity. 3-day dasatinib treatment enhanced the tumor-specific T
cell priming while 8-day dasatinib treatment suppressed this T cell response. Next, we
explored when combined with anti-OX40, which regimen could achieve better
therapeutic effect. The survival curve clearly indicated that the combination of 3-day
dasatinib with anti-OX40 provided better therapeutic effect than the combination of 8day dasatinib with anti-OX40(Figure 23A and 23B). This result is consistent with our
expectation: with short-term treatment, tumor antigen-specific T cells prime and largely
exist in the circulation which later on are attracted into tumor microenvironment with the
help of anti-OX40; however, in mice treated with long-term dasatinib, the level of tumorspecific T cells in the circulation is comparatively low, therefore, CTLs attracted into
tumor microenvironment are not many.
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Figure 23 Therapeutic effects of short-term dasatinib combined with anti-OX40
treatment versus long-term dasatinib treatment combined with anti-OX40.
(A) Tumor sizes in mice for 3 different groups. (B) Kaplan-Meier survival curves of mice
for 3 different groups. (3-day dasatinib + anti-OX40 versus 8-day dasatinib + anti-OX40:
*P = 0.05).
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Chapter 4. Discussion and future directions

4.1 Summary and discussion
Starting with the observation that the anti-tumor effect of dasatinib in P815 mastocytoma
model largely relied on the presence of T cells, we subsequently found that short-term
dasatinib treatment could induce a potent tumor specific-T cell response. We next
identified the mechanism by which dasatinib promoted the priming of tumor-specific T
cells, which was through the attenuation of certain immunosuppressive factors, including
Treg cells and IL-10. The addition of anti-OX40 further potentiated this anti-tumor
immune response by increasing CTL migration into the tumor microenvironment. The
combination of dasatinib and anti-OX40 turned out to be a potent therapy which resulted
in tumor clearance in most of the treated mice. This study demonstrates a strategy by
which targeted drug and immune-based therapy can be combined to achieve better antitumor responses and provides experimental evidence to support moving this
combinatorial regimen into clinical trials.

The therapeutic effect of molecular targeted drugs has long been believed to be primarily
due to direct tumoricidal effects from oncogenic pathway blockade. However, in our
study we show that, in addition to the direct cytotoxic effects of targeted therapy drugs,
an underlying immune response also contributed significantly to the tumor eradication in
our model. We observed that 3-day dasatinib treatment triggered a potent anti-tumor T
cell response, and that depletion of CD4+ or CD8+ T cells resulted in a significant
blunting of the anti-tumor effect of dasatinib. This result is consistent with the recent
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emerging  notion  that  preserving  patients’  immune  function  during  the  administration  of  
cancer therapy regimens might help achieving optimal therapeutic effects.

A major area of concern relates to deleterious off-target effects of small molecule
tyrosine kinase inhibitors, including the potentially suppressive effect of these drugs on
immune cells. In particular, dasatinib has been shown to inhibit antigen-dependent T cell
proliferation both in vitro and in vivo (137, 138, 147), and this negative effect has been
attributed  to   dasatinib’s  inhibitory   effect   on  the   activity  of   the Src family member Lck,
which plays a critical role in the TCR signal transduction pathway (138). Other studies
have shown that dasatinib treatment in vitro decreased ERK and Akt activity in T cells
upon TCR stimulation (137). However, evidence from clinical practice suggests that this
drug may not be entirely immunosuppressive. A clinical study showed that in CML and
Ph+ ALL patients treated with dasatinib, a significant proportion of the patients
developed marked lymphocytosis which was attributed to the clonal expansion of NK
cells and cytotoxic T cells(148). In addition, one of the most common side effects of
dasatinib is pleural effusion, a potentially immune-mediated reaction wherein high
numbers of lymphocytes are found in the pleural fluid of patients (149). The apparent
discrepancy between the clinical experience and studies in animal models may be due to
differences in the treatment schedule and dose. Our study addresses this paradoxical issue.
We found that 3 day-dasatinib treatment stimulated a potent tumor antigen-specific T cell
response; however, 8 day-dasatinib treatment suppressed the development of the T cell
response. When combined with an immunomodulatory antibody anti-OX40, the
therapeutic effect of long-term dasatinib treatment was even worse than short-term
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treatment. This suggested that prolonged inhibition of T cells caused by persistent
administration of the tyrosine kinase inhibitor might be undesirable, considering that
preserving patients’ anti-tumor immunity is beneficial. Under normal circumstances, T
cell response peaks around day 6-8 days after antigen encounter. When we gave mice
dasatinib for 3 days, we created a short-term  window  of  ‘low  Treg/  T  effector  ratio’  and  
‘low  IL-10  level’,  which  provided  T  cells  with  a  better  opportunity  to  mount  an  effective  
response. However, when we treated mice with dasatinib for  8  days,  we  didn’t  release  T  
cells from dasatinib inhibition within the requisite timeframe. Therefore, the T cell
response was suppressed by the prolonged administration of dasatinib. The comparative
dynamics of T cell response and drug administration are demonstrated in the below graph
(Figure 24). In the combination experiment, we found that the therapeutic effect of 8-day
dasatinib plus anti-OX40 treatment was actually worse than 3-day dasatinib plus antiOX40 treatment. This result is consistent with our anticipation that short-term treatment
elicits strong endogenous T cell response, which can be potentiated by the addition of
anti-OX40. However, long-term treatment suppresses the development of the T cell
response,  which  doesn’t  work  as  well  as  short-term treatment when combined with antiOX40. These data suggest that optimization of dosing and schedule is a critical factor in
order to achieve maximal therapeutic effect from combining targeted therapy with
immunotherapy.

It has been previously believed that sustained target inhibition is a driving principle for
targeted therapy. However, whether continuous administration of a targeted therapy drug
is necessary has been recently questioned. Studies suggest that intermittent or high-dose
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pulse treatment may provide certain therapeutic advantages. One study showed that, in a
xenograft model of melanoma positive for the BRAF V600E mutation, persistent
administration of vermurafenib conferred the development of drug resistance, but
intermittent treatment prevented the emergence of drug resistance(150). It is speculated
that selective pressure exerted by prolonged drug treatment, is one of the prerequisites for
tumor cells acquiring resistance. Therefore, the continuous treatment actually favors the
development of drug resistance by providing this kind of selective pressure. However,
intermittent administration of a targeted therapy drug may avoid this effect. Another
study showed that, in BCR-ABL mutant CML cell lines, 20 minute high-dose pulse
dasatinib treatment and 48 hour low-dose continuous treatment provided equivalent
cytotoxicity in vitro. This suggested that once the threshold of target inhibition is
exceeded,  the  ‘oncogenic  shock’  can  initiate  an  irreversible  cell  death  program  to  commit  
cancer cells to death; and this threshold can be exceeded by either extending the
treatment time or increasing the inhibition magnitude(151). These results support
potential clinical utility of intermittent administration of a targeted therapy drug. In
addition, our study showed that short-term dasatinib treatment can elicit strong anti-tumor
T cell response, while long-term treatment, which exerts prolonged inhibitory effect on
immune cells, actually compromised the development of anti-tumor immunity. Therefore,
in the combination treatment setting, a high-dose pulse or intermittent treatment may be
superior to continuous administration.

Next we further explored the mechanism of how dasatinib induced a strong anti-tumor T
cell response. In the P815 model, we found that dendritic cells from dasatinib-treated
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mice didn’t present more tumor antigen than their counterparts from the untreated control
group, suggesting that the difference in the magnitude of the T cell response was not
caused by the first step of T cell priming - which was in contrast with our prior
hypothesis. Release of a plethora of proteins from dying tumor cells is normally
considered a good resource of tumor antigens for potential T cell priming. Furthermore,
several studies have shown that cytotoxic drug regimens could elicit underlying antitumor immune responses (131). However, tumor cells can die in multiple ways, including
apoptosis, necrosis and autophagy, and there is no consensus about which form of cell
death is the most capable of stimulating potent anti-tumor immune responses(152).
Emerging evidence demonstrates that immunogenicity of the tumor death might depend
on the integration of multiple co-existing signals in a localized context. Zitvogel and
colleagues have conducted a series of extensive studies about cell death as induced by
chemotherapy and irradiation therapy. This has led to a concept known as ‘immunogenic  
cell  death   (ICD)’  which  indicates   that the cells undergoing apoptosis deliver a series of
immunogenic signals which stimulate APCs to efficiently take up the tumor antigens,
process and present them to T cells, thereby eliciting an immune response against the
tumor (153). Several immunogenic factors delivered by cells undergoing ICD have been
identified, including exposure of an ER chaperone protein Calreticulin (CRT) on the
tumor cell surface and the release of ATP and HMGB1, a well-known damage-associated
molecular pattern (DAMP) protein (154-156). In light of these results, it is possible that
dasatinib-induced P815 tumor cell death is not inducing ICD. Another possibility is, the
antigen-presenting capability of DCs is compromised by dasatinib. The effect of dasatinib
on the DC function of taking up, processing, and presenting antigen has not yet been
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reported. But there are studies showing that c-KIT activation in DC enhanced the
production of IL-6 which in turn promoted Th2/ Th17 responses; blocking c-KIT
signaling helped skew the response toward Th1 direction, suggesting that c-KIT signaling
might play a critical role in regulating DC function (157). It also has been shown that
imatinib can inhibit DC differentiation and priming of CTL responses in vitro, but it is
unclear whether this could be attributed to the inhibition of c-KIT (158, 159).
Considering dasatinib and imatinib have partially overlapping kinase target spectrums, it
is possible that dasatinib also suppresses DC function, and the increased tumor antigen
released after dasatinib treatment was offset by the inhibitory effect of dasatinib on DC
function. The exact effect of dasatinib on the immunogenicity of P815 tumor death and
DC function needs to be further studied. However, in this model the enhanced T cell
priming did not appear to be caused by increased tumor antigen presentation.

Next, we examined Treg levels in these mice, since dasatinib has been shown to inhibit
Treg proliferation and suppressive function in vitro (139). Tregs can suppress immune
effector cells and are critical mediators of cancer immune tolerance. Tregs were first
identified by the Sakaguchi group as a CD4+ T cell subset expressing Foxp3 and high
levels of CD25 (160-162). They comprise about 5-10% of the peripheral CD4+ T cell
population. Regulatory T cells can be further classified as naturally occurring Treg
(nTreg) which are derived from the thymus and induced Treg (iTreg) which develop from
conventional CD4+ T cells. Tregs can strongly inhibit the activation, expansion, cytolytic
activity and cytokine production of effector T cells. Mechanisms for the suppressive
function of Tregs include expression of IL-10 and TGF-β, releasing granzymes and
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perforin to induce the apoptosis of effector cells, and producing cAMP and adenosine to
disrupt the normal metabolism of effector cells. In addition, Tregs can also modulate the
activation status of dendritic cells to indirectly suppress effector T cell priming (163-165).
Many studies have shown that cancer cells can subvert immune-mediated control by
promoting and

recruiting Tregs,

and Treg levels

in

circulation or tumor

microenvironment are inversely correlated with the prognosis of patients with various
types of cancer(166). Therefore, down-regulation of Treg levels or function could
directly influence the magnitude of an anti-tumor immune response and the outcome of
anti-tumor therapy (167-173).

In our study, we found that Treg cells were more sensitive than effector T cells to
dasatinib inhibition, and 3-day dasatinib treatment significantly decreased the Treg/CD4+
and Treg/CD8+ ratios in the blood of the mice. The intratumoral Treg levels were also
down-regulated following dasatinib treatment. When we pre-treated mice with vehicle or
dasatinib for 3 days then gave P1A peptide-pulsed DC vaccine, the antigen-mediated
CD8+ T cell response was significantly higher in dasatinib-pre-treated mice. This
experiment suggests that suppression of Tregs might be one mechanism mediating the
enhanced anti-tumor T cell response after dasatinib treatment. The homeostatic
proliferation, survival and function of Treg cells depends on multiple external signals,
including TCR, IL-2R, CD28, CTLA-4 and other less-characterized pathways (174). Lck,
a tyrosine kinase that plays a critical role in the TCR signaling pathway, is also known to
be important for Treg homeostasis and function. Mice with a conditional null allele of
Lck in the Treg compartment have significantly reduced number of Treg cells, and their
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proliferation capability and immunosuppressive function are also impaired (175). Since
Lck activity is strongly inhibited by dasatinib in effector T cells (137), it is possible that
dasatinib also inhibits Lck activity in Treg cells which leads to the reduced number and
function of those cells. It is also possible that other unidentified tyrosine kinases involved
in Treg proliferation, survival and function are inhibited by dasatinib, which will require
further experimental exploration to determine. Activation of the OX40 signal has been
shown to attenuate the suppressive function of Treg cells (99-101); Consistent with this,
our experiment showed that dasatinib combined with anti-OX40   exerted   a   ‘dual  
inhibition   ’effect   on   the   function   of   Treg   cells.   Therefore,   an   additional   benefit   of
combining these two agents together may lie in the down-regulation of Treg levels and
function.

One may also speculate that other tyrosine kinase inhibitors may also have a similar
effect of enhancing underlying anti-tumor immune response when being administered
properly, since many of them have been shown to exert inhibitory effects on
immunosuppressive cells. For example, imatinib, sunitinib and sorafeinib have all been
shown to inhibit Treg proliferation or suppressive function(130, 176, 177). However,
they have also been reported to negatively interfere with T effector cells(178).
Considering these drugs have partially overlapping target spectrum with dasatinib, given
that they all inhibit Src family members, the underlying molecular mechanisms mediating
the immunomodulatory effect may be similar. Additionally, sunitinib is known to
potently suppress MDSC function and accumulation in cancer patients.(130). Whether
these drugs can also be combined with immunotherapy to achieve synergistic therapeutic
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effect requires further study. We speculate that one advantage of dasatinib, compared to
other tyrosine kinase inhibitors, is its short-half life. The overall mean terminal half-lives
of other tyrosine kinase inhibitors are typically 2 to 3 days, while dasatinib has a half-life
of 5-6 hours.(39). This may prove to be therapeutically advantageous when combined
with

immunotherapy.

Because

prolonged

half-life

may

lead

to

prolonged

immunosuppression, short half-life may lead to transient immunosuppression. Feasible
combinations of long half-life tyrosine kinase inhibitors with immunotherapy need
further experimental exploration. Again, the dosing and schedule is an essential factor to
consider in combining long half-life tyrosine kinase inhibitors with immunotherapy.

We also explored how dasatinib affected the immune microenvironment of P815 tumors.
From microarray and luminex assays, we found that IL-10 levels were significantly
down-regulated at the tumor site. IL-10 has been shown to exert pleiotropic effects on
both adaptive and innate immune responses, and it is generally considered a negative
regulator of anti-tumor immune responses. Many different types of cancer cells directly
produce IL-10, and systemic IL-10 level is negatively correlated with prognosis in
multiple cancer types (179-183). IL-10 is known to impair the antigen presenting
capability of DCs by suppressing the surface expression of HLA class II molecules and
certain positive costimulatory molecules (for example, CD80 and CD86),

and up-

regulating certain negative costimulatory molecules (for example, PD-L1)(184, 185). It
has also been shown that IL-10-treated dendritic cells can induce T cell anergy after
antigen presentation (186). IL-10 can also down-regulate HLA class I and class II in
certain types of cancer, which reduces tumor recognition by cytolytic T cells (187, 188).
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IL-10 can suppress T cell proliferation by reducing the production of IL-2 and IFN-γ
(189). Furthermore, IL-10 is not only the major mediator of Treg suppressive function,
but also involved in the proliferation and differentiation of certain subsets of Tregs(190192). In addition, IL-10 can enhance HLA-G surface expression on tumor cells, which
prevents tumor lysis by NK cells (193). Therefore, tumor-derived IL-10 has long been
considered as an important factor in cancer immune escape. Our in vivo experiments also
showed that blocking IL-10 could ameliorate immunosuppression and enhance the
endogenous anti-tumor T cell response. Since P815 itself produces significant amounts of
IL-10, eradication of tumor cells would directly lead to a decrease of this
immunosuppressive cytokine within the tumor microenvironment. This could be an
important contributing factor to the tumor-specific T cell response induced upon
dasatinib treatment. The ability to relieve immune suppression could be considered as
another beneficial mechanism provided by targeted therapy drugs.

Recently emerging evidence suggests links between oncogenic signaling and
immunosuppression in cancer. For example, MAPK signaling pathway in BRAF mutant
melanoma cell lines has been shown to promote the production of IL-10, VEGF and IL-6,
which are immunosuppressive soluble factors, and overexpression of PD-L1 in tumor
microenvironment(129, 144). Therefore, MAPK signaling is considered as a critical
mechanism through which melanoma immune evasion is mediated. PTEN loss and
hyperactivity of PI3K/Akt pathway have been shown to increase PD-L1 expression in
colon cancer cell lines and melanoma cell lines(194, 195). STAT3 activation has been
shown to be associated with the expansion and function of MDSC in the tumor
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microenvironment(196). The MAPK pathway, PI3K/Akt pathway and JAK/STAT
pathway are all frequently activated in cancers and c-KIT signaling has been shown to
activate these pathways in various types of cancer cells.(17). Therefore, it is possible that
the down-regulation of c-KIT could directly suppress the activation of these pathways,
thereby alleviating immunosuppression in the tumor microenvironment. Although this
has not been observed in our tumor model, exploration of potential links between c-KIT
oncogenic signaling and cancer immunosuppression in other cancer models is still
desirable. These studies can lead to a better understanding of the signaling pathways
driving immunosuppression, and could pave the way for utilizing c-KIT inhibitors to
subvert cancer immunosuppression in combination treatment settings.

Effective T cell priming alone is not sufficient to induce potent anti-tumor immune
responses, because adequate migration of CTLs into the tumor microenvironment is also
essential for tumor cell eradication. For example, cancer vaccines can successfully induce
the generation of large numbers of tumor-specific T cells in the circulation, but still
usually fail to provide significant therapeutic benefit (197). In addition, extensive
infiltration of tumor-reactive immune cells is often correlated with better prognosis in
patients. For example, in melanoma, ovarian and colon cancers, CD8+ T cell infiltration
can serve as a strong positive prognostic marker (198, 199).

These lines of evidence

demonstrate that presence of CTL within the tumor microenvironment is crucially
important for an effective anti-tumor response.
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Two recent studies have shown that administration of agonistic anti-OX40 antibody
potentiated CD8+ T cell infiltration and suppressed Treg infiltration in murine tumors (88,
104). In our study, anti-OX40 treatment did not significantly affect the clonal expansion
of tumor-specific T cells, but we did observe increased percentages and absolute numbers
of CD8+ T cells at tumor sites in mice from the anti-OX40 treatment group, which is
consistent   with   the   ‘enhancing-migration’   function   suggested   by the above-mentioned
studies. In addition, the combination of dasatinib and anti-OX40 increased the
percentages and absolute numbers of P1A-specific T cells, and decreased the Treg/CD8+
T cell ratio within the tumor microenvironment. Therefore, the major effect of antiOX40 in this mouse model seems to be potentiating anti-tumor T cell responses by
enhancing the recruitment of CTL into tumor microenvironment. Considering that
impaired CTL trafficking has been shown to be a rate-limiting step for cancer
immunotherapy, anti-OX40 might be a promising therapeutic agent to boost the clinical
efficacy of this approach.

T cell migration is a complicated multi-step process which involves a number of
molecules. The repertoire of chemokines is a key factor determining the migration and
infiltration of T cells into tumor sites. In particular, the CXCR3 - CXCL9/10/11 axis is
known to play an important role in CD8+ T cell chemotaxis and homing to tumors.
CXCL9, 10 and 11 are T cell chemoattractants induced by IFN-γ (200), and CXCR3 is a
chemokine receptor preferentially expressed by Th1 cells. Ligation of CXCR3 with those
chemokines induces integrin activation and cellular cytoskeletal changes which promote
the chemotactic migration of T cells (201). In our study, we demonstrated that this
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combinatorial regimen significantly up-regulated the expression of CXCL9, 10 and 11 at
tumor sites. Furthermore, high levels of those cytokines correlated well with the high
levels of tumor-specific T cells in tumors treated with the combinatorial regimen, which
is consistent with our prediction that the tumor microenvironment is made more
permissive due to the induction of these cytokines. At this time, the exact mechanism by
which the combination of dasatinib and anti-OX40 enhances the level of Th1 cytokines is
not clear. But there is one report showing that activating the OX40 signaling pathway can
directly induce the expression of CXCL9 by vascular endothelial cells at the tumor site,
suggesting that one possible mechanism of anti-OX40 enhancing CTL trafficking is
through augmenting Th1 chemokine signals. Our results support a model that dasatinib,
OX40, CTL, IFN-γ  and  CXCL9, 10 and 11 compose a positive feedback loop in which
dasatinib leads to increased tumor-specific T cells in the circulation; the OX40 signal
enhances the migration of CTL into the tumor sites by inducing the expression of CXCL9;
large amounts of IFN-γ  are produced after CTLs encounter antigen on tumor cells; IFN-γ  
further up-regulates CXCL9, 10 and 11, which bring more CTLs into the tumor
microenvironment and produces more IFN-γ  and  IFN-γ-induced chemokines (Figure 25).
Therefore, treatment with dasatinib plus anti-OX40 promotes T cell responses at both the
priming and trafficking stages, explaining the superior therapeutic effect of this
combination.
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Figure 24 Comparative dynamics of T cell response and dasatinib administration.

104

Figure 25 Mechanism underlying the anti-tumor effect of the combination of
dasatinib and anti-OX40.
Tumor antigens are phagocytosed by mDCs which present them to T cells and drive the
activation and expansion of tumor-specific T cells. Dasatinib suppresses Treg cells and
down-regulates IL-10 levels in the tumor microenvironment, which helps T cell prime
better. Anti-OX40 also exerts inhibitory effect on Treg cells. Anti-OX40 provides a
costimulatory signal, which augments the migration of circulating tumor-specific
cytotoxic T cells into the tumor microenvironment. CTL release IFN-γ after encounter
tumor cells and IFN-γ up-regulates the expression levels of CXCL9,10 and 11 which
further bring more CTL into tumor microenvironment. Tumor cells are eradicated by the
tumor antigen-specific T cells in the tumor microenvironment.

This is a modified version of a figure originally published in Oncoimmunology. Yang Y,
Lizée G, Hwu P. Strong emerging rationale for combining oncogene-targeted agents with
immunotherapy. Oncoimmunology. 2013 Feb 1;2(2):e22730. © Landes Bioscience
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4.2 Future directions
The results presented in this thesis together with other related studies give rise to several
other questions calling for further validation. Studies analyzing the interaction between
targeted therapy drugs and the anti-tumor immune response will provide guidance to
clinical practice in the future.

Treg cells are one of the most important immunosuppressive components for tumorinduced tolerance. Numerous studies have demonstrated the benefit of eliminating Treg
cells for improving the efficacy of cancer immunotherapy. In this study, we show that
dasatinib has strong anti-Treg function, which might make this drug a good candidate for
integration into cancer immunotherapy strategies. However, the molecular mechanism of
dasatinib-mediated Treg inhibition is poorly understood. It is not known whether Lck is
the molecular mediator of this inhibitory effect. Since Tregs are more sensitive to
dasatinib inhibition than effector T cells, do Treg cells have higher Lck dependence than
T effector cells? Are there any other tyrosine kinases involved? Further work
characterizing the proteomic and transcriptional changes after dasatinib treatment in Treg
cells will help to answer those questions.

It also would be valuable to monitor the level and function of T effector cells and Treg
cells  from  patients  treated  with  dasatinib.  This  will  ascertain  if  the  similar  ‘low  Treg/  T  
effector  ratio’  window  exists in the bodies of human beings to facilitate development of
immune response against tumor. Phenotypic characterization of those cells will also help
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to determine the potential clinical value of combining this drug with immunotherapy.
More pre-clinical and clinical studies are needed to determine the optimal doses and
schedules of dasatinib administration before applying the combination in patient
treatment. Since there are other tyrosine kinase inhibitors - for example imatinib,
sorafenib and sunitinib - that show suppressive effect on Tregs, these drugs are also
potentially able to reverse immunosuppression in the combination therapy setting,
although this awaits further experimental validation.

With the advent of the animal model in which mice spontaneously develop GIST owing
to the mutant c-KIT gene, scientists have been able to study the interaction between
imatinib and the host anti-GIST immune response (128). It would be interesting to try the
combination of imatinib/dasatinib and anti-OX40 to observe the therapeutic effect and
see whether the a similar positive feedback loop composed of targeted agent, CTL, IFN-γ  
and Th1 cytokines can be generated in this model. Since a humanized anti-OX40
antibody is now available, these studies will pave the way for translating the combination
of c-KIT inhibitor and anti-OX40 into GIST clinical trials. Since melanoma is the most
responsive cancer to immunotherapy, further development of mouse c-KIT mutant
melanoma models is desirable, which will offer opportunities of conducting preclinical
studies testing the feasibility of using this combination to treat melanoma patients.

Our work and that of others have shown that agonistic OX40 antibody can boost the
migration of CTL into the tumor microenvironment. However, the exact mechanism
underlying this phenomenon is largely unknown. It would be interesting to characterize
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OX40 expression by the various subsets of cells in both human and murine tumor
microenvironments and study the phenotypic changes to these cells before and after
OX40 activation both in vitro and in vivo. OX40 or OX40L conditional knockout mice
could be utilized to identify the cellular mediators for the enhanced migration of CTL to
the tumor site induced by OX40 activation. Those studies would help to evaluate the
potential clinical utility of applying agonistic anti-OX40 antibody for cancer treatment.

Several recent publications have reported that combinations of targeted therapy and
immunotherapy provide a synergistic therapeutic effect in various tumor models. BRAF
inhibitor PLX4032 was shown to synergize with adoptive T cell therapy in a melanoma
mouse model (202). Another c-KIT inhibitor imatinib combined with anti-CTLA-4
provided superior anti-tumor effect in a GIST mouse model (128). The result of a GIST
clinical trial combining imatinib and IFN-α  also  appears very promising (203). However,
more studies are needed to understand the interaction between various targeted therapy
drugs and host immune responses. Most importantly, optimization of the dosing and
scheduling for these treatments is needed to achieve maximal therapeutic effect. More
speculatively, future animal studies and clinical trials can be conducted to combine
cytokine-based therapy, cancer vaccines, adoptive T cell therapy and antibodies against
other co-stimulatory or checkpoint molecules with molecular targeted drugs.
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Chapter 5. Methods and materials
Cell lines, reagents, and animals
P815 murine mastocytoma cells were obtained from ATCC (Manassas, VA). All tumor
cell lines were maintained in MEM (Life Technologies, Grand Island, NY) with 10%
FBS (Atlanta Biologicals, Lawrenceville, GA)  and  100μg/ml  Normocin  (Invivogen,  San  
Diego, CA). DBA/2 mice, 6-10 weeks old, were purchased from National Cancer
Institute (Bethesda, MD) and maintained in a pathogen-free animal facility at M. D.
Anderson Cancer Center. P1CTL transgenic mice were provided by Dr. Yang Liu
(University of Michigan Health System, Ann Arbor, MI). Mice were handled in
accordance with protocols approved by the Institutional Animal Care and Use Committee.
Dasatinib was purchased from LC Laboratories (Woburn, MA) and dissolved in vehicle
(50% Polyethylene glycol, 50%H2O) before gavage. Anti-OX40 antibody was purchased
from Harlan (Indianapolis, IN). CD8 depletion antibody (clone HB129/116-13.1), CD4
depletion antibody (clone GK1.5), anti-IL-10 blocking antibody (clone JES5-2A5), antiCTLA-4 antibody (clone 9H10), anti-PD-1 antibody (clone J43) and Rat IgG 2b isotype
control antibody were purchased from Bioxcell (West Lebanon, NH).

Reagents for flow cytometric analysis
Flow cytometric analysis was performed using the following antibodies: FITCconjugated   αCD3,   APC-conjugated   αCD8,   PE-conjugated   αIFN-γ,   FITC-conjugated
αCD11c,   APC-conjugated   αCD11b,   Percp-Cy5.5-conjugated   αCD11b,   APC-conjugated
αAnnexin   V   and   Annexin   V   binding buffer were purchased from BD Bioscience (San
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Jose, CA); APC-conjugated   αFoxp3,   PerCP-Cy5.5-conjugated   αCD25,   PE-conjugated
αCD4,   FITC-conjugated   αCD8,   Pacific   Blue-conjugated   αCD8,   APC-conjugated
αCD117, APC-conjugated  αGr-1, FITC-conjugated  αLy6C  and 7-AAD viability staining
solution were purchased from eBioscience (San Diego, CA); PE-conjugated P1A
tetramer was synthesized at the MHC Tetramer Production Facility of Baylor College of
Medicine (Houston, TX). IFN-γ   and   Treg   staining   was   performed   according to the
protocol provided by the manufacturers (BD Bioscience and eBioscience). Cells were
analyzed using the BD Caton II flow cytometer, with data analyzed by using BD Diva
software.

Tumor inoculation and immunotherapy
DBA/2 mice were subcutaneously inoculated with 2×106 P815 tumor cells on the left
abdominal wall on day 0. Mice with moderate tumor size were selected and divided into
different groups on day 8 (6-10 mice in each group). Tumor-bearing mice were treated
with vehicle or dasatinib (150mg/kg) on day 8, 9 and 10 by gavage. In the combination
treatment experiments, mice were also injected intraperitoneally with anti-OX40 antibody
(200μg/mice),  anti-PD-1  antibody  (200μg/mice),  anti-CTLA-4  antibody  (100μg/mice)  on  
day 10 and 13. Tumor growth was monitored by measuring the perpendicular diameters
of tumors. Mice were sacrificed when the tumor diameters exceeded 20 mm. For CD4+/
CD8+T cell-depletion experiments, tumor-bearing mice were injected intraperitoneally
with  200μg  of  monoclonal  antibodies starting from day 8 once a week. Rat IgG was used
as control antibody. Depletion of CD4+ and CD8+T cells was confirmed by analyzing
the peripheral blood of the mice by flow cytometry. For IL-10 blocking experiment,
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tumor-bearing mice were injected intraperitoneally   with   200μg   of   IL-10 blocking
antibody starting from day 8 twice a week.

Monitoring tumor antigen-specific T cell response
On   day   14,   18,   21   and   26,   50μl   of   peripheral   blood   was   collected   by   using   tail-clip
method and then treated with ACK lysis buffer (Cambrex, Walkersville, MD) for 5
minutes   to   deplete   the   red   blood   cell.   Cells   were   stained   with   αCD3,   αCD8   and   P1A  
tetramer antibodies. For IFN-γ   intracellular   staining,   cells   were   stimulated   with   or  
without   10μg/ml   P1A   or   P1E   peptide   in   the   presence of 1:1000 Golgiplug (BD
Bioscience)   for   6   hours.   Cells   were   then   collected   and   stained   with   αCD3,   αCD8   and  
αIFN-γ  antibodies.  The  percentage  of  antigen-specific T cells was analyzed by using flow
cytometry. In another experiment, collected peripheral blood cells were stimulated with
or without P1A or P1E peptide (Peptides International, Louisville, KY) for 24 hours. The
supernatants were harvested and the concentration of IFN-γ  was  detected  by  ELISA.  The  
IFN-γ   ELISA   kit   was   purchased   from   Biolegend   (San Diego, CA) and the experiments
were  conducted  according  to  manufacturer’s  instruction.

T cell CFSE proliferation assay and IFN-γ  release  assay
Splenocytes from P1CTL transgenic mice were harvested and labeled with 1µM CFSE
(Invitrogen, Carlsbad, CA) for 5 minutes at 37 ºC. After being washed with PBS,
splenocytes  were  cultured  with  10μg/ml  P1A  peptide  in  the  presence  of  0nm,  1nm,  5nm,  
10nm, 25nm or 50nm dasatinib. Two days later, CFSE dilution was analyzed by BD
Caton II flow cytometer. Splenocytes were also harvested and cultured in the presence of
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250 units/ml human interleukin-2 Proleukin (Chiron, Emeryville, California) and 0.3
μg/ml  anti-mouse CD3 (BD Bioscience, San Jose, CA) for 7 days. More than 95% of the
cultured cells were CD8+ P1A-specific T cells  after  7  days’  culture.  Then  the  effector  T  
cells were cultured alone or with P815 tumor cells as 1:1 ratio or in the presence of 10
μg/ml   P1A   peptide   for   24   hours   in   96-well round bottom plates. Supernatants were
harvested and concentration of IFN-γ was detected by ELISA.

Dendritic cell antigen presenting assay
Mice were treated with vehicle or dasatinib for 2 days. On day3, left inguinal lymph
nodes which are the tumor draining lymph nodes and right inguinal lymph nodes which
are the non-draining lymph  nodes  were  harvested  and  stained  with  αCD11c  and  αCD11b.  
Double positive cells were sorted out by FACS and cocultured in 96-well round bottom
plate together with P1A-specific T cells which had been cultured with IL-2 and anti-CD3
for 7 days. 1:1000 Golgiplug was added in the culture. Eight hours later, cells were
collected  and  stained  with  αCD8  and  αIFN-γ  antibodies  and  analyzed  by  flow  cytometry.

Dendritic cell vaccination
Murine bone marrow cells were grown in complete medium with 100ng/ml GM-CSF for
8  days  then  stimulated  with  1μg/ml  LPS  for  1  day.  Non-adherent cells were collected and
resuspended in Opti-MEM Medium (Life Technologies, Grand Island, NY) at a
concentration of 2×106 cells/ml,   and   pulsed   with   10   μg/ml   P1A   peptide for 4 hours at
37°C. On day-3, 3 million splenocytes from P1CTL transgenic mice were transferred
into DBA/2 mice via intravenous injection. Then mice were treated with vehicle or
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dasatinib for 3 days. On day 0, 1 million P1A peptide-pulsed DCs were transferred into
DBA/2 mice. Peripheral blood was collected on day 7 for flow cytometric analysis.

C-KIT knockdown
C-KIT was knocked down by ON-TARGETplus SMARTpool (Thermo Scientific,
Pittsburgh, PA). P815 cells were transfected with the Cell Line Nucleofector Kit T
(Lonza, Allendale, NJ) by using program C-013 according to manufacturer’s  instruction.
Concentrations of the mouse c-KIT siRNA pool and non-targeting pool were 2µM. And
2μg  of  pmaxGFP  vector  in  the  kit  was  also  used  for  transfection  to  check  the  transfection  
efficiency. Flow cytometric analysis 24 hours after electroporation indicated that
transfection efficiency was higher than 80%. 24 hours later, the cells were stained with
αCD117  (c-KIT) antibody and analyzed by flow cytometry.

Taqman Realtime PCR for C-KIT
Cells were harvested 24 hours after siRNA transfections. RNA was isolated by using
RNAeasy   mini   Kit   (Qiagen,   Valencia,   CA)   according   to   manufacturer’s   instruction.
CDNA synthesis was done by using Cloned AMV first-strand cDNA synthesis kit
(Invitrogen, Rockville, MD ). Taqman Realtime PCR was carried out using 7500 Fast
Realtime PCR machine (Applied Biosystems, Foster city, CA). Primer for c-KIT and
GAPDH were purchased from life technologies(Grand Island, NY). Data analysis was
performed using 7500 Fast system software.

Microarray analysis and Luminex assay
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P815 tumors were harvested 24 hours after vehicle or dasatinib treatment. There were 2
tumors in each group. Cultured P815 cells were harvested 24 hours and 36 hours after
being transfected with siRNA. P815 tumor cells were also treated with DMSO or 25nm
dasatinib in vitro for 24 hours and then collected. Samples were snap-frozen in liquid
nitrogen and sent to Expression Analysis (Durham, NC) for microarray analysis by using
the Mouse WG6 arrays (Illumina, San Diego, CA). In P815 tumor samples, to identify
differentially expressed genes between tumors treated with vehicle and tumors treated
with dasatinib, we calculated the mean of the QS-normalized, background-subtracted,
log2 transformed signals of the 2 samples. Heatmaps were made by Cluster 3.0 and
viewed by TreeView, displaying the 20 most differentially expressed immune-related
genes selected based on the fold change of the mean. For Luminex assay, tumors were
harvested after 3-day dasatinib treatment. Tumor masses were homogenized and then
sonicated in lysis buffer which contained protease inhibitors. After centrifuge, the tumor
lysates were used for the analysis of multiple cytokines by multiplex Luminex assay
(Aushon Biosystems, Woburn, MA).The experiment was conducted according to
manufacturer’s  instruction .

Immunohistochemistry
Tumors were harvested after 3-day vehicle or dasatinib treatment. Samples were
embedded in OCT and snap-frozen in liquid nitrogen. Immunohistochemistry was done
by Research Histopathology Facility at M. D. Anderson.

Harvest of tumor infiltrating lymphocytes
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On day 16, tumors were harvested and dissected into fragments by cutting, and then
digested in tumor digestion buffer for 2 hours at 37ºC. The tumor digestion buffer was
made by dissolving 1mg/ml collagenase, 100µg/ml hyaluronidase and 20mg/ml DNase
(Sigma-Aldrich, St. Louis, MO) in RPMI medium. Then tumor digests were filtered
through 70µm nylon mesh. Cell suspensions were layered over the Lympholyte-M
density separation medium (Cedarlane, Hornby, Ontario, Canada) and centrifuged at
1000g for 20 minutes. Lymphocyte layers at the interface were isolated and analyzed by
flow cytometry.

SYBR Green Realtime PCR for chemokines
Total RNA was isolated from tumors on day 16 after tumor inoculation by using
RNAeasy mini Kit (Qiagen, Valencia, CA) according to the protocol provided by the
manufacturer. Cloned AMV first-strand cDNA synthesis kit (Invitrogen, Rockville, MD )
was used for cDNA synthesis. SYBR Green Realtime PCR was done by using Bio-Rad
C1000 Thermal cycler (Bio-rad, Hercules, CA ). And the panel of chemokine primers is
shown below (Table 4). The chemokines on the Realtime PCR panel include CCL1-13,
CCL17, CCL19-22, CCL24-25, CCL27-28, CXCL1-2, CXCL4-5, CXCL7, CXCL9-16,
XCL1 and CX3CL1. GAPDH was used as the normalization reference gene. Data
analysis was performed using Bio-Rad CFX manager software.
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Table 4 List of the chemokine primers for realtime PCR

This table was originally published in Cancer Research. Peng W, Liu C, Xu C, Lou
Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P. PD-1
blockade enhances T-cell migration to tumors by elevating IFN-γ  inducible  
chemokines. Cancer Research. 2012; 72(20): 5209-18. © the American Association
for Cancer Research
.
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Treg suppression assay
Mice were treated with 3 doses of vehicle or dasatinib (150 mg/kg) and 1 dose of antiOX40 (200 µg/mice). After that, splenocytes of the mice were collected and stained with
αCD4,  αCD8,  αCD25  antibodies.  CD4+ CD25high cells from the 4 different groups were
sorted out as Treg cells by flow cytometry, and CD8+ cells were sorted out as effector T
cells. Effector T cells were labeled with 1µM CFSE for 5 minutes at 37°C. Sorted Treg
cells and effector T cells were co-cultured at a 2:1 ratio in 96-well round bottom plate
with non-T cell splenocytes as APCs, 30IU/ml IL-2  and  0.1μg/ml  αCD3.  Three  days  later,  
cells were analyzed for CFSE dilution by flow cytometric analysis.

Statistical analysis
Data are represented as mean ± SEM. The statistical differences between different groups
were determined by the Student's T test or one way ANOVA test in GraphPad Prism
software. Mouse survival between groups was compared by using the Log-rank test in
GraphPad Prism software.
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